WO1997023600A9 - A conjugate vaccine against gram-negative bacterial infections - Google Patents
A conjugate vaccine against gram-negative bacterial infectionsInfo
- Publication number
- WO1997023600A9 WO1997023600A9 PCT/US1996/019747 US9619747W WO9723600A9 WO 1997023600 A9 WO1997023600 A9 WO 1997023600A9 US 9619747 W US9619747 W US 9619747W WO 9723600 A9 WO9723600 A9 WO 9723600A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pilin
- gram
- pilo
- dna
- pili
- Prior art date
Links
- 229960005486 vaccines Drugs 0.000 title claims abstract description 56
- 206010060945 Bacterial infection Diseases 0.000 title claims description 24
- 108010000916 Fimbriae Proteins Proteins 0.000 claims abstract description 165
- 241000347881 Kadua laxiflora Species 0.000 claims abstract description 101
- 101710012627 pilO Proteins 0.000 claims abstract description 101
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims abstract description 67
- 241000894006 Bacteria Species 0.000 claims abstract description 56
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 8
- 241001377010 Pila Species 0.000 claims description 60
- 108060003458 ftsY Proteins 0.000 claims description 59
- 102000004965 antibodies Human genes 0.000 claims description 45
- 108090001123 antibodies Proteins 0.000 claims description 45
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 239000000427 antigen Substances 0.000 claims description 29
- 230000003899 glycosylation Effects 0.000 claims description 28
- 238000006206 glycosylation reaction Methods 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 26
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 24
- 230000014509 gene expression Effects 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 239000002773 nucleotide Substances 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 241000894007 species Species 0.000 claims description 13
- 108020004511 Recombinant DNA Proteins 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 102000038129 antigens Human genes 0.000 claims description 10
- 108091007172 antigens Proteins 0.000 claims description 10
- 238000009396 hybridization Methods 0.000 claims description 10
- 238000003752 polymerase chain reaction Methods 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 238000009631 Broth culture Methods 0.000 claims description 8
- 238000003745 diagnosis Methods 0.000 claims description 8
- 229920000023 polynucleotide Polymers 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 238000009007 Diagnostic Kit Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 230000001580 bacterial Effects 0.000 claims description 5
- 238000011031 large scale production Methods 0.000 claims description 5
- -1 nucleotide triphosphates Chemical class 0.000 claims description 5
- 230000001681 protective Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 239000000546 pharmaceutic aid Substances 0.000 claims description 4
- 239000001226 triphosphate Substances 0.000 claims description 4
- 235000011178 triphosphate Nutrition 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 230000001131 transforming Effects 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 230000001668 ameliorated Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 abstract description 21
- 230000001279 glycosylating Effects 0.000 abstract description 3
- 230000000241 respiratory Effects 0.000 abstract description 2
- 238000011176 pooling Methods 0.000 abstract 1
- 210000004027 cells Anatomy 0.000 description 43
- 239000002158 endotoxin Substances 0.000 description 37
- 235000018102 proteins Nutrition 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 31
- 239000000523 sample Substances 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 19
- 229920001850 Nucleic acid sequence Polymers 0.000 description 18
- 210000002966 Serum Anatomy 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 238000004166 bioassay Methods 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 235000000346 sugar Nutrition 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl β-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 9
- 210000001519 tissues Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 8
- 108010045030 monoclonal antibodies Proteins 0.000 description 8
- 230000002103 transcriptional Effects 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 102000004854 Immunoglobulin M Human genes 0.000 description 7
- 239000000020 Nitrocellulose Substances 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 102000005614 monoclonal antibodies Human genes 0.000 description 7
- 229920001220 nitrocellulos Polymers 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 241001594857 Pao Species 0.000 description 6
- 229920001949 Transfer RNA Polymers 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 239000002609 media Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- HEGSGKPQLMEBJL-RQICVUQASA-N (2R,3S,4S,5R)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol Chemical compound CCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RQICVUQASA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 108020004999 Messenger RNA Proteins 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 5
- 108020004566 Transfer RNA Proteins 0.000 description 5
- 230000000240 adjuvant Effects 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000000875 corresponding Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 229920002106 messenger RNA Polymers 0.000 description 5
- 229960000060 monoclonal antibodies Drugs 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 4
- SSJMZMUVNKEENT-IMJSIDKUSA-N Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CO SSJMZMUVNKEENT-IMJSIDKUSA-N 0.000 description 4
- 230000002378 acidificating Effects 0.000 description 4
- 238000009632 agar plate Methods 0.000 description 4
- 230000000890 antigenic Effects 0.000 description 4
- 244000052616 bacterial pathogens Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000001155 isoelectric focusing Methods 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000006011 modification reaction Methods 0.000 description 4
- 235000013930 proline Nutrition 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108010080629 tryptophan-leucine Proteins 0.000 description 4
- XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 210000003495 Flagella Anatomy 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 description 3
- 108010079364 N-glycylalanine Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920000978 Start codon Polymers 0.000 description 3
- 230000003115 biocidal Effects 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000002759 chromosomal Effects 0.000 description 3
- 238000010192 crystallographic characterization Methods 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 230000002068 genetic Effects 0.000 description 3
- 108010050848 glycylleucine Proteins 0.000 description 3
- 230000002209 hydrophobic Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 230000001264 neutralization Effects 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 230000001717 pathogenic Effects 0.000 description 3
- 244000052769 pathogens Species 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 108091007521 restriction endonucleases Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 230000018290 type IV pilus-dependent motility Effects 0.000 description 3
- IOUPEELXVYPCPG-UHFFFAOYSA-N val-gly Chemical compound CC(C)C(N)C(=O)NCC(O)=O IOUPEELXVYPCPG-UHFFFAOYSA-N 0.000 description 3
- 230000017613 viral reproduction Effects 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MPZWMIIOPAPAKE-UHFFFAOYSA-N 4-amino-5-[[1-carboxy-4-(diaminomethylideneamino)butyl]amino]-5-oxopentanoic acid Chemical compound OC(=O)CCC(N)C(=O)NC(C(O)=O)CCCN=C(N)N MPZWMIIOPAPAKE-UHFFFAOYSA-N 0.000 description 2
- FSHURBQASBLAPO-WDSKDSINSA-N Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)N FSHURBQASBLAPO-WDSKDSINSA-N 0.000 description 2
- WUGMRIBZSVSJNP-UFBFGSQYSA-N Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UFBFGSQYSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 210000003719 B-Lymphocytes Anatomy 0.000 description 2
- 229960003669 Carbenicillin Drugs 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N Carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- 210000000170 Cell Membrane Anatomy 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 101710019325 GDI2185 Proteins 0.000 description 2
- PFMUCCYYAAFKTH-YFKPBYRVSA-N Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CN PFMUCCYYAAFKTH-YFKPBYRVSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- VYZAGTDAHUIRQA-WHFBIAKZSA-N L-alanyl-L-glutamic acid Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O VYZAGTDAHUIRQA-WHFBIAKZSA-N 0.000 description 2
- HFKJBCPRWWGPEY-BQBZGAKWSA-N L-arginyl-L-glutamic acid Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HFKJBCPRWWGPEY-BQBZGAKWSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 description 2
- NTISAKGPIGTIJJ-IUCAKERBSA-N Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(C)C NTISAKGPIGTIJJ-IUCAKERBSA-N 0.000 description 2
- VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 description 2
- BQVUABVGYYSDCJ-ZFWWWQNUSA-N Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-ZFWWWQNUSA-N 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- QXOHLNCNYLGICT-YFKPBYRVSA-N Met-Gly Chemical compound CSCC[C@H](N)C(=O)NCC(O)=O QXOHLNCNYLGICT-YFKPBYRVSA-N 0.000 description 2
- PBOUVYGPDSARIS-IUCAKERBSA-N Met-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C PBOUVYGPDSARIS-IUCAKERBSA-N 0.000 description 2
- 206010028347 Muscle twitching Diseases 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 101700036978 OMP Proteins 0.000 description 2
- 210000001322 Periplasm Anatomy 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- HMNSRTLZAJHSIK-YUMQZZPRSA-N Pro-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 HMNSRTLZAJHSIK-YUMQZZPRSA-N 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 229960002180 Tetracycline Drugs 0.000 description 2
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- UYKREHOKELZSPB-JTQLQIEISA-N Trp-Gly Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(O)=O)=CNC2=C1 UYKREHOKELZSPB-JTQLQIEISA-N 0.000 description 2
- LYMVXFSTACVOLP-ZFWWWQNUSA-N Trp-Leu Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C([O-])=O)=CNC2=C1 LYMVXFSTACVOLP-ZFWWWQNUSA-N 0.000 description 2
- GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 2
- STTYIMSDIYISRG-WDSKDSINSA-N Val-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(O)=O STTYIMSDIYISRG-WDSKDSINSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 102000029988 adhesion receptors Human genes 0.000 description 2
- 108010013985 adhesion receptors Proteins 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 108010070944 alanylhistidine Proteins 0.000 description 2
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 108010077245 asparaginyl-proline Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000023298 conjugation with cellular fusion Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 101700064522 eaeA Proteins 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- KZNQNBZMBZJQJO-YFKPBYRVSA-N gly pro Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 2
- 102000035362 glycosylated proteins Human genes 0.000 description 2
- 108091005600 glycosylated proteins Proteins 0.000 description 2
- 108010081551 glycylphenylalanine Proteins 0.000 description 2
- 108010077515 glycylproline Proteins 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108010091871 leucylmethionine Proteins 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 150000002632 lipids Chemical group 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 108010005942 methionylglycine Proteins 0.000 description 2
- 238000005497 microtitration Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 108091008117 polyclonal antibodies Proteins 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 101700050745 rpoN Proteins 0.000 description 2
- 101710006293 rpoN1 Proteins 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 101710044770 sll1951 Proteins 0.000 description 2
- 230000000392 somatic Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 108010038745 tryptophylglycine Proteins 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 230000021037 unidirectional conjugation Effects 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- RXGLHDWAZQECBI-SRVKXCTJSA-N (2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- IGROJMCBGRFRGI-YTLHQDLWSA-N (2S)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]propanoyl]amino]propanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 1
- XMAUFHMAAVTODF-STQMWFEESA-N (2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 XMAUFHMAAVTODF-STQMWFEESA-N 0.000 description 1
- FPTXMUIBLMGTQH-ONGXEEELSA-N 2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 FPTXMUIBLMGTQH-ONGXEEELSA-N 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N 2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]propanoyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- XUUXCWCKKCZEAW-YFKPBYRVSA-N 2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 description 1
- VWHGTYCRDRBSFI-ZETCQYMHSA-N 2-[[2-[[(2S)-2-amino-4-methylpentanoyl]amino]acetyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N Actinospectacin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- CCUAQNUWXLYFRA-IMJSIDKUSA-N Ala-Asn Chemical compound C[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC(N)=O CCUAQNUWXLYFRA-IMJSIDKUSA-N 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 description 1
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- BUQICHWNXBIBOG-LMVFSUKVSA-N Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)N BUQICHWNXBIBOG-LMVFSUKVSA-N 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 108020005098 Anticodon Proteins 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- SIFXMYAHXJGAFC-WDSKDSINSA-N Arg-Asp Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O SIFXMYAHXJGAFC-WDSKDSINSA-N 0.000 description 1
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
- QADCERNTBWTXFV-JSGCOSHPSA-N Arg-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCNC(N)=N)N)C(O)=O)=CNC2=C1 QADCERNTBWTXFV-JSGCOSHPSA-N 0.000 description 1
- XTWSWDJMIKUJDQ-RYUDHWBXSA-N Arg-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XTWSWDJMIKUJDQ-RYUDHWBXSA-N 0.000 description 1
- XNSKSTRGQIPTSE-UHFFFAOYSA-N Arginyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CCCNC(N)=N XNSKSTRGQIPTSE-UHFFFAOYSA-N 0.000 description 1
- GADKFYNESXNRLC-WDSKDSINSA-N Asn-Pro Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GADKFYNESXNRLC-WDSKDSINSA-N 0.000 description 1
- SONUFGRSSMFHFN-IMJSIDKUSA-N Asn-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O SONUFGRSSMFHFN-IMJSIDKUSA-N 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- DYDKXJWQCIVTMR-UHFFFAOYSA-N Aspartyl-Methionine Chemical compound CSCCC(C(O)=O)NC(=O)C(N)CC(O)=O DYDKXJWQCIVTMR-UHFFFAOYSA-N 0.000 description 1
- 229920000195 Bacterial small RNA Polymers 0.000 description 1
- 229940052491 Bordetella pertussis Drugs 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- ZSRSLWKGWFFVCM-WDSKDSINSA-N Cys-Pro Chemical compound SC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O ZSRSLWKGWFFVCM-WDSKDSINSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108009000097 DNA Replication Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-N Deoxycytidine triphosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000606006 Dichelobacter Species 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 101700079760 EFCB Proteins 0.000 description 1
- 101710005090 ERVFC1-1 Proteins 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 101710013371 ERVS71-1 Proteins 0.000 description 1
- 206010014013 Ear infection Diseases 0.000 description 1
- 241000588877 Eikenella Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 101700012711 FMI Proteins 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 1
- YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 description 1
- UQHGAYSULGRWRG-WHFBIAKZSA-N Glu-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(O)=O UQHGAYSULGRWRG-WHFBIAKZSA-N 0.000 description 1
- LLEUXCDZPQOJMY-AAEUAGOBSA-N Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(O)=O)=CNC2=C1 LLEUXCDZPQOJMY-AAEUAGOBSA-N 0.000 description 1
- SCCPDJAQCXWPTF-VKHMYHEASA-N Gly-Asp Chemical compound NCC(=O)N[C@H](C(O)=O)CC(O)=O SCCPDJAQCXWPTF-VKHMYHEASA-N 0.000 description 1
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 1
- JBCLFWXMTIKCCB-VIFPVBQESA-N Gly-Phe Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-VIFPVBQESA-N 0.000 description 1
- AJHCSUXXECOXOY-NSHDSACASA-N Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-NSHDSACASA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- LYCVKHSJGDMDLM-LURJTMIESA-N His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 LYCVKHSJGDMDLM-LURJTMIESA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000745 Immune Sera Proteins 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 241001454354 Kingella Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine zwitterion Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 101700048016 LAC12 Proteins 0.000 description 1
- 101710019425 LARS2 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- MLTRLIITQPXHBJ-BQBZGAKWSA-N Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O MLTRLIITQPXHBJ-BQBZGAKWSA-N 0.000 description 1
- HIZYETOZLYFUFF-BQBZGAKWSA-N Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O HIZYETOZLYFUFF-BQBZGAKWSA-N 0.000 description 1
- OTXBNHIUIHNGAO-UWVGGRQHSA-N Leu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN OTXBNHIUIHNGAO-UWVGGRQHSA-N 0.000 description 1
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 206010061229 Lung infection Diseases 0.000 description 1
- UGTZHPSKYRIGRJ-YUMQZZPRSA-N Lys-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UGTZHPSKYRIGRJ-YUMQZZPRSA-N 0.000 description 1
- YSZNURNVYFUEHC-BQBZGAKWSA-N Lys-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YSZNURNVYFUEHC-BQBZGAKWSA-N 0.000 description 1
- JPNRPAJITHRXRH-UHFFFAOYSA-N Lysyl-Asparagine Chemical compound NCCCCC(N)C(=O)NC(C(O)=O)CC(N)=O JPNRPAJITHRXRH-UHFFFAOYSA-N 0.000 description 1
- 108010060534 MSH (11-13) Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- WEDDFMCSUNNZJR-WDSKDSINSA-N Met-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O WEDDFMCSUNNZJR-WDSKDSINSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 229940051866 Mouthwash Drugs 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine;hydron;chloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine zwitterion Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 1
- 229940052778 Neisseria meningitidis Drugs 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 229960005030 OTHER VACCINES in ATC Drugs 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 1
- BXNGIHFNNNSEOS-UWVGGRQHSA-N Phe-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 BXNGIHFNNNSEOS-UWVGGRQHSA-N 0.000 description 1
- ROHDXJUFQVRDAV-UWVGGRQHSA-N Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 ROHDXJUFQVRDAV-UWVGGRQHSA-N 0.000 description 1
- JMCOUWKXLXDERB-WMZOPIPTSA-N Phe-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 JMCOUWKXLXDERB-WMZOPIPTSA-N 0.000 description 1
- IEHDJWSAXBGJIP-RYUDHWBXSA-N Phe-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 IEHDJWSAXBGJIP-RYUDHWBXSA-N 0.000 description 1
- KNPVDQMEHSCAGX-UHFFFAOYSA-N Phenylalanyl-Cysteine Chemical compound SCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 KNPVDQMEHSCAGX-UHFFFAOYSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N Phenylalanyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- JQOHKCDMINQZRV-WDSKDSINSA-N Pro-Asn Chemical compound NC(=O)C[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 JQOHKCDMINQZRV-WDSKDSINSA-N 0.000 description 1
- ZKQOUHVVXABNDG-IUCAKERBSA-N Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 ZKQOUHVVXABNDG-IUCAKERBSA-N 0.000 description 1
- BEPSGCXDIVACBU-UHFFFAOYSA-N Prolyl-Histidine Chemical compound C1CCNC1C(=O)NC(C(=O)O)CC1=CN=CN1 BEPSGCXDIVACBU-UHFFFAOYSA-N 0.000 description 1
- 241000169446 Promethis Species 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241001098565 Pseudomonas aeruginosa PA103 Species 0.000 description 1
- 241001620960 Pseudomonas aeruginosa PAK Species 0.000 description 1
- 108010079005 RDV peptide Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- LTFSLKWFMWZEBD-IMJSIDKUSA-N Ser-Asn Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O LTFSLKWFMWZEBD-IMJSIDKUSA-N 0.000 description 1
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 description 1
- PPQRSMGDOHLTBE-UWVGGRQHSA-N Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PPQRSMGDOHLTBE-UWVGGRQHSA-N 0.000 description 1
- WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 description 1
- SBMNPABNWKXNBJ-UHFFFAOYSA-N Serinyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CO SBMNPABNWKXNBJ-UHFFFAOYSA-N 0.000 description 1
- LZLREEUGSYITMX-UHFFFAOYSA-N Serinyl-Tryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C(CO)N)C(O)=O)=CNC2=C1 LZLREEUGSYITMX-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- VPZKQTYZIVOJDV-LMVFSUKVSA-N Thr-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(O)=O VPZKQTYZIVOJDV-LMVFSUKVSA-N 0.000 description 1
- BQBCIBCLXBKYHW-CSMHCCOUSA-N Thr-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O BQBCIBCLXBKYHW-CSMHCCOUSA-N 0.000 description 1
- QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 description 1
- KAFKKRJQHOECGW-JCOFBHIZSA-N Thr-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(O)=O)=CNC2=C1 KAFKKRJQHOECGW-JCOFBHIZSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- CKHWEVXPLJBEOZ-UHFFFAOYSA-N Threoninyl-Valine Chemical compound CC(C)C(C(O)=O)NC(=O)C(N)C(C)O CKHWEVXPLJBEOZ-UHFFFAOYSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 210000003437 Trachea Anatomy 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- DZHDVYLBNKMLMB-ZFWWWQNUSA-N Trp-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 DZHDVYLBNKMLMB-ZFWWWQNUSA-N 0.000 description 1
- IMMPMHKLUUZKAZ-WMZOPIPTSA-N Trp-Phe Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=CC=C1 IMMPMHKLUUZKAZ-WMZOPIPTSA-N 0.000 description 1
- SMDQRGAERNMJJF-UHFFFAOYSA-N Tryptophyl-Cysteine Chemical compound C1=CC=C2C(CC(N)C(=O)NC(CS)C(O)=O)=CNC2=C1 SMDQRGAERNMJJF-UHFFFAOYSA-N 0.000 description 1
- KBUBZAMBIVEFEI-UHFFFAOYSA-N Tryptophyl-Histidine Chemical compound C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CN=CN1 KBUBZAMBIVEFEI-UHFFFAOYSA-N 0.000 description 1
- YSGSDAIMSCVPHG-YUMQZZPRSA-N Val-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)C(C)C YSGSDAIMSCVPHG-YUMQZZPRSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 229940118696 Vibrio cholerae Drugs 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000002457 bidirectional Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000003391 densitometric scan Methods 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 230000002222 downregulating Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 101710004779 fba1 Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- VPZXBVLAVMBEQI-VKHMYHEASA-N gly ala Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
- STKYPAFSDFAEPH-LURJTMIESA-N gly-val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CN STKYPAFSDFAEPH-LURJTMIESA-N 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine zwitterion Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 108010084389 glycyltryptophan Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-J lipid A(4-) Chemical compound O1[C@H](CO)[C@@H](OP([O-])([O-])=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP([O-])([O-])=O)O1 GZQKNULLWNGMCW-PWQABINMSA-J 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 108010076718 lysyl-glutamyl-tryptophan Proteins 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010044655 lysylproline Proteins 0.000 description 1
- 201000009906 meningitis Diseases 0.000 description 1
- 108010068488 methionylphenylalanine Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 244000039328 opportunistic pathogens Species 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000000242 pagocytic Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 108010083476 phenylalanyltryptophan Proteins 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 101700016463 pls Proteins 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000001323 posttranslational Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 102000034363 protein filaments Human genes 0.000 description 1
- 108091005958 protein filaments Proteins 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 230000029610 recognition of host Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 101700025964 sspA Proteins 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 108010010318 streptococcal M protein Proteins 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000004642 transportation engineering Methods 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 108010029384 tryptophyl-histidine Proteins 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 200000000019 wound Diseases 0.000 description 1
- SITLTJHOQZFJGG-XPUUQOCRSA-N α-Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O SITLTJHOQZFJGG-XPUUQOCRSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Definitions
- Pseudomonas aeruginosa is recognized as a leading cause of life- threatening infection among compromised patient populations in hospitals. Cancer patients, and patients with burn wounds, cystic fibrosis, acute leukemia, organ transplants, and intravenous-drug addiction are particularly susceptible to acquiring a serious P. aeruginosa infection.
- the most serious infections include pneumonia, septicemia, malignant-external otitis, and meningitis.
- the mortality rate for such infections can exceed 50%, and is usually the highest for any bacterial pathogen (Cryz, S. J., Jr. In Pseudomonas aeruginosa as an Opporunistic Pathogen. Mario Campa et al., Eds. Plenum Press, New York, 1993, pp. 383-395. All documents cited herein infra and supra are hereby incorporated by reference thereto).
- aeruginosa is an opportunistic pathogen, therefore, a key component of this bacterium's pathogenicity is the ability of the microorganisms to adhere to epithelial cells of mucosal surfaces (E. H. Blackey, 1981, J Infect. Dis. 143: 325-345).
- the somatic pili of P. aeruginosa, protein filaments clustered around the flagellum and extending from the cell surface, have been implicated in adherence to host tissue (Ramphal et al., 1984, Infect. Immun. 44: 38-40; Woods et al., 1980, Infect. Immun. 29: 1 146-1 151). Pili are composed of monomeric subunits.
- pilin which have a molecular weight of 15-18000 daltons (Frost and Paranchych, 1977, J. Bacteriol.131 : 259-269; Sastry et al. , 1983, FEBS Lett 151:253-256; Sastry et al. .1985, J. Bacteriol. 164:571-577) and are arranged in a helical fashion within the pilus fiber (Watts et al. .1983, Biochemistry 22: 3640-3646).
- the pilins of P. aeruginosa are similar in structure and function to those produced by many Gram-negative bacteria such as species of the genera Dichelobacter (Elleman, T. C. 1988 Microbiol. Rev.
- Eikenella (Rao and Progulske-Fox, 1993 J. Gen. Microbiol. 139: 651-660), Kingella (Weir and Marrs, 1992, Infect. Immun. 60: 3437- 3441 ), Moraxella (Marrs et al. 1985, J. Bacteriol. 163: 132-139), Neisseria (Meyer et al., 1984, Proc. Natl. Acad. Sci. USA 81: 61 10-61 14), and Vibrio (Faast et al., 1989, Gene 85: 227-231).
- pilin is encoded by a single chromosomal copy (Pasloske et al., 1985, FEBS Lett. 183: 408-412; Sastry et al., 1985, J. Bacteriol. 164: 571-577), the pilA gene.
- the nucleotide sequence of several P. aeruginosa pilA genes is known and comparisons of deduced pilin primary structure and flanking DNA sequence have shown characteristic variation which allows differentiation of P.
- group I such as pili strain 1244
- group II pilins PA103, T2A, PAO, PAK pilins
- group I pilin determinants were relatively common (58/95 and include different strains of different immunotypes as determined by polyclonal antibody reaction) among clinical isolates.
- P. aeruginosa pili as a vaccine presents many advantages. Unlike previous lipopolysaccharide-based Pseudomonas vaccines, pili produce minimal side effects and are well known to be immunogenic in humans, possibly due to antigen organization (Bachman, et al. ,1993, Science 262: 1448-1451) brought about by subunit arrangement in the fiber. Much is known of the biochemistry and molecular biology of the pili and the technology is available for the identification and characterization of pilus epitopes. Pili can be prepared easily in homogeneous form and methods described in this application allow large scale production of pili which are compatible with modern forms of vaccine delivery such as microencapsulation. The P.
- aeruginosa pili can be engineered to act as "carriers" for other protein epitopes. thereby conferring the advantages of pili to other antigens; DNA sequences coding for known protein epitopes (outer membrane proteins for example) could be used to replace known surface pilin epitopes by PCR methodologies.
- the advantages of peptide technology can be applied to pilus vaccines. Cocktails of peptide epitopes can be constructed to deal with antigenic variation seen in serotype populations.
- the present invention relates to a pilus-based vaccine and is based on recent work showing that pili from group I strains of P. aeruginosa, a clinically common group, are glycosylated and that pili glycosylation may be involved in specific or nonspecific adhesion to the host cell independent of pilin protein- mediated attachment (Castric, P. , 1995, Microbiology 141: 1247- 1254).
- Glycosylated pili are shown to produce high bronchial titers when delivered by the intranasal route. Mice vaccinated with pure P. aeruginosa strain 1244 pili in this manner are protected against respiratory challenge with P. aeruginosa strain 1244. More specifically, the present invention relates to a new gene sequence, pilO, the product of which glycosylates the pili of P. aeruginosa strains by adding the specific O-antigen components of the lipopolysaccharide (LPS) carried by that strain onto the pili resulting in antigenic glycosylated pili useful as a vaccine against infection with that strain.
- LPS lipopolysaccharide
- This ORF, called pilO was flanked by a tRNA lhr gene, which was followed by a transcriptional termination sequence.
- the tRNA thr gene and the termination sequence were nearly identical to sequences found immediately adjacent to the pilA gene of several P. aeruginosa strains.
- Hyperexpression of the pilA gene in a pilO ' strain resulted in normal pilus-specific phage sensitivity and twitching motility, two other functions of pili.
- the pilin produced by this strain however had a lower apparent Mr and a more neutral pi compared to that produced by a strain containing a functional pilO gene. This pilin failed to react with a sugar-specific reagent which recognized pilin produced by the strain containing a functional pilO gene (Castric, P., 1995, Microbiology 141 : 1247- 1254).
- pilO is specific for strain 1244 pilin.
- strain 1244 will produce strain PA 103 pili (a group II pilin) from a plasmid carrying the cloned gene, but will not glycosylate the PA 103 pilin protein.
- pilO is not specific for the O-antigen attached to the strain 1244 pilin. pilO will glycosylate strain 1244 pili with the LPS O-antigen repeating units of other P. aeruginosa strains.
- strain PAK another group II strain
- strain 1244 pilin gene carrying a plasmid retaining both the pilO gene and strain 1244 pilin gene
- strain 1244 pili carrying the chemically and serologically distinctive strain PAK O-antigen.
- the potential for O- antigen range of glycosylation is extremely wide and can extend to virtually any Gram-negative bacterium, P. aeruginosa and other species.
- pilin glycosylation allows the design of vaccines specific for different strains of P. aeruginosa, or of Gram-negative bacteria, by the addition to the pilin core of the specific glycan produced in the bacteria for which a vaccine is desired and using the resulting pili as a vaccine.
- Other vaccines presently being studied are composed of the LPS associated with the O-antigen.
- the use of an LPS based vaccine has several serious drawbacks as compared to the use of glycosylated pili as a vaccine. Glycosylated pili contain the immunogenic portion (O-antigen) but not the toxic part (lipid A) of the LPS molecule resulting in a safer, better tolerated vaccine.
- the range of protection of a cocktail of glycosylated pili will be broader than a cocktail of LPS due to the common epitopes of the pilus protein. Protection will be both pilus based and O-antigen based. LPS purification is time consuming, expensive and difficult. Glycosylated pili can be produced in large amounts by a new method described in this application involving the use of broth cultures instead of the commonly used agar cultures. Purification of glycosylated pili is quickly accomplished, inexpensive, and requires only common laboratory procedures.
- the design of a pilus vaccine and understanding the immunological relationship among native pili is dependent on the ability to determine which parts of the pilus surface make up the B-cell epitopes.
- the positions of the protein B-cell epitopes of the native strain 1244 pili were determined using the Geysen tethered peptide pin assay as described in Castric and Deal, 1994, supra.
- Four epitope regions were revealed representing the portions of the piiin primary structure which occupy the surface of the pilus fiber. These sequences would be important in peptide vaccine design. Two of these sequences, region 3 (SEQ LD NO: 3) and region 4 (SEQ ID NO: 4) may also represent glycosylation recognition sequences according to recent results from peptide mapping of PilA.
- the pilO protein is capable of glycosylating any protein which contains the pilin glycosylation recognition sequence.
- the sequence can be inco ⁇ orated in several ways, for example, using PCR methods, the pilin glycosylation recognition sequence can be inserted into a gene of a known surface protein; this engineered gene can be inco ⁇ orated into the chromosome of the host by gene replacement, and pilO hyperexpressed from a broad host range plasmid such as pPAC46 which grows and functions in nearly all Gram- negative bacteria.
- It is another object of the invention to provide a recombinant vector comprising a vector and the above described DNA fragment functionally positioned next to a pilin gene, preferably the pilin gene of strain 1244.
- It is yet another object of the present invention to provide a method for the diagnosis of Gram-negative bacterial infection comprising the steps of: (i) contacting a sample from an individual suspected of having the disease with antibodies which recognize glycosylated pilin or an attached glycan of Gram-negative bacteria; and
- reaction mixture comprising:
- Figure 1 shows sequence homology of the region downstream from the pilO gene, with the region downstream of the pilA gene of P. aeruginosa strain PA103 (Johnson et al., 1986, 7. Biol. Chem. 261: 15703-15708). Colons indicate base homology. Regions containing significant dyad symmetry are indicated by opposing arrows. The tRNA gene region is highlighted.
- Figure 2 shows a comparison of the pilin gene regions of P. aeruginosa strain 1244 and strain PA 103. Potential transc ⁇ ptional stops are indicated by the letter "t”. Restriction endonuclease sites are H, HindlLT; N, Nhel. P, Pstl; S, Sphl.
- Figure 3 is a Northern blot analysis of mRNA extracted from P. aeruginosa strain 1244.
- A. Probes were prepared from restriction fragments of cloned DNA indicated in the Fig. 2 map as follows: Lane 1, Probe 1 (the Sphl-Nhel fragment); Lane 2, Probe 2 (the Nhel-Pstl fragment); Lane 3, Probe 3 (the Pstl-HindUl fragment). Arrows indicate positions of E. coli strain ⁇ B101 ⁇ bosomal RNA.
- B Densitometric scan of lane 1 of panel A of this figure. Scanning was from bottom to top of the autoradiogram shown. Electrophoresis point of origin is marked by the arrow
- Figure 4 shows immunodetection of electrophoretically separated P. aeruginosa pilin.
- A SDS-PAGE of pilin at 5°C. Lane 1 , 3 ⁇ g pilin produced by P. aeruginosa strain 1244N3(pPAC46), Lane 2, 3 ⁇ g pilin produced by P aeruginosa strain 1244N3(pPAC24). Molecular weights are given as times
- P. aeruginosa strain 1244N3(pPAC24) Lane 2, 3 ⁇ g pilin produced by P. aeruginosa strain 1244N3(pPAC46).
- the p ⁇ gradient was determined by focusing pi standards on an identical gel in the absence of octyl glucoside.
- Figure 5 shows the detection of P. aeruginosa pilin carbohydrate by immunoblot. Lane 1 , 10 ⁇ g pilin produced by P. aeruginosa strain 1244N3(pPAC46), Lane 2, 10 ⁇ g pilin produced by P. aeruginosa strain 1244N3(pPAC24). Molecular weights are given as times 10 " ⁇ Arrows indicate positions of these pilins on an identical blot using monoclonal antibody 6-45 for detection.
- Figure 6 Gel filtration of protease digested strain 1244 pili.
- Figure 7 Competition ELISA (glycan vs native pili) using monoclonal antibodies 1 1.14 and 5.44.
- Figure 8 Major epitopes of P. aeruginosa 1244 pilus as determined by the Geysen pin test.
- the present invention relates to a DNA or cDNA segment which encodes pilO, a glycosylation sequence of pilA pilin core protein.
- the sequence of the gene, specified in SEQ LD NO: 1 was obtained by sequencing a region downstream from the P. aeruginosa 1244 pilA gene.
- the sequenced gene fragment comprising 1386 nucleotides of open reading frame with a 60.1 % G+C content consistent with the general range given for P. aeruginosa chromosomal DNA.
- DNA or polynucleotide sequences to which the invention also relates include sequences of at least about 6 nucleotides, preferably at least about 8 nucleotides, more preferably at least about 10-12 nucleotides, most preferably at least about 15-20 nucleotides corresponding, i.e., homologous to or complementary to, a region of the pilO nucleotide sequence.
- sequence of the region from which the polynucleotide is derived is homologous to or complementary to a sequence which is unique to the pilO gene. Whether or not a sequence is unique to the pilO gene can be determined by techniques known to those of skill in the art.
- the sequence can be compared to sequences in databanks, e.g., GenBank.
- Regions from which typical DNA sequences may be derived include but are not limited to, for example, regions encoding specific epitopes, as well as non-transcribed and/or non-translated regions.
- the derived polynucleotide is not necessarily physically derived from the nucleotide sequence shown in SEQ ID NO: 1 , but may be generated in any manner, including for example, chemical synthesis or DNA replication or reverse transcription or transcription, which are based on the information provided by the sequence of bases in the region(s) from which the polynucleotide is derived.
- sequences of the present invention can be used in diagnostic assays such as hybridization assays and polymerase chain reaction assays and for the discovery of other pilO sequences.
- the present invention relates to a recombinant
- DNA molecule that includes a vector and a DNA sequence as described above.
- the vector can take the form of a plasmid such as any broad host range expression vector for example pMMB66EH and others known in the art.
- the present invention relates to host cells stably transformed or transfected with the above-described recombinant DNA constructs.
- the host cell can be any Gram-negative bacteria for which glycosylated pilin is desired.
- the vector containing the pilO gene is expressed in the bacteria and the product of the pilO gene is able to add subunits of the specific O-antigen of the host bacteria to the core pilin producing glycosylated pilins which can be isolated for use as a vaccine and in diagnostic assays.
- the plasmid pPAC46 described below in Materials and Methods, containing both the pilA and pilO wherein the pilA gene of strain 1244 was placed downstream from the tac promoter (in such a way as to inactivate the pilA promoter) of the broad host range expression vector pMMB66EH (Furste, et al, 1986, Gene 48: 1 19-131) results in high levels of glycosylated pilus production by hyper-expression of the pilA gene.
- Promoters other than the tac promoter include ⁇ P L promoter, T7 promoter, and MalE promoter. Please see e.g., Maniatis, Fitsch and Sambrook, Molecular Cloning: A Laboratory Manual (1982) or DNA Cloning.
- the DNA sequence can be present in the vector operably linked to a highly purified IgG molecule, an adjuvant, a carrier, or an agent for aid in purification of glycosylated pilin.
- the transformed or transfected host cells can be used as a source of DNA sequences described above.
- the recombinant molecule takes the form of an expression system
- the transformed or transfected cells can be used as a source of the protein described below.
- the present invention relates to a pilO protein having an amino acid sequence corresponding to SEQ LD NO: 2 and encompassing 461 amino acids or any allelic variation thereof.
- a polypeptide or amino acid sequence derived from the amino acid sequence in SEQ LD NO:2 refers to a polypeptide having an amino acid sequence identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least 2-5 amino acids, and more preferably at least 8- 10 amino acids, and even more preferably at least 1 1-15 amino acids, or which is immunologically identifiable with a polypeptide encoded in the sequence.
- a recombinant or derived polypeptide is not necessarily translated from a designated nucleic acid sequence, or the sequence in SEQ LD NO: 1 ; it may be generated in any manner, including for example, chemical synthesis, or expression of a recombinant expression system.
- the polypeptide can be fused to other proteins or polypeptides for example, MalE protein for transport into the periplasm or for secretion from the cell.
- the present invention relates to a method of producing glycosylated pilin which includes culturing the above-described host cells, under conditions such that the DNA fragment is expressed and a glycan specific for such host cells is added to the core pilin protein producing glycosylated pilin.
- the glycosylated pili can then be isolated using methodology well known in the art or by the new large scale production method described below.
- the glycosylated pili can be used as a vaccine for immunity against infection with the host bacteria or as a diagnostic tool for detection of host bacterial infection.
- the transformed host cells can be used to analyze the effectiveness of drugs and agents which inhibit adhesion of host bacteria to cells, such as host proteins or chemically derived agents or other proteins which may interact with the bacteria to down-regulate or alter the expression of pilO or affect the ability of pili to adhere to cells.
- a method for testing the effectiveness of a drug or agent capable of inhibiting the adhesion of the Gram-negative bacteria being studies can be for example the adhesion assay of Deal and Krivan, Met. Enzymol. 236: 346-353.
- the present invention relates to antibodies specific for the above-described glycosylated pili. For instance, an antibody can be raised against the complete glycosylated pili or against a portion thereof.
- proteins or polypeptides examples include any adjuvants or carriers safe for human use, such as aluminum hydroxide.
- the present invention relates to a method of detecting the presence of Gram-negative bacterial infection or antibodies against Gram-negative bacteria in a sample.
- a diagnostic assay can be constructed by coating on a surface (i.e. a solid support) for example, a microtitration plate or a membrane (e.g. nitrocellulose membrane), all or a unique portion of the glycosylated pili described above, for example the O-antigen, and contacting it with the serum of a person suspected of having a Gram-negative bacterial infection.
- the presence of a resulting complex formed between glycosylated pili and antibodies specific therefor in the serum can be detected by any of the known methods common in the art, such as fluorescent antibody spectroscopy or colo ⁇ metry. This method of detection can be used, for example, for the diagnosis and typing of Gram- negative bacterial infections.
- the adhesion properties of the Gram-negative bacte ⁇ a are critical to its virulence and central to the development of pathology. Consequently, the ability of an individual to reduce bactenal adhesion would determine the patient's ability to prevent infection or disease.
- This may take the form of antibodies which inhibit the adhesion of pili to cells; this can be measured in an assay for the detection of glycosylated pili as described below. Such assays can be used to screen individuals after receiving a Gram-negative vaccine to measure the production of protective antibodies.
- Another mechanism to reduce adhesion of pili to cells is by down-regulating or altering the adhesion receptors present on the cells.
- Glycosylated pili can be used to measure the availability of cell receptors by contacting labeled glycosylated pili to target tissue either ex vivo or in vivo and measuring the degree to which labeled pili bind to target tissue.
- Pili can be labeled by any detectable label known in the art such as a radionuc de, for example.
- pili, glycosylated or unglycosylated can be used as receptor analogs to block the adhesion receptors present on host cells, thereby reducing or inhibiting the adhesion of bacteria to host cells. These pili can be administered in a mouthwash for example.
- the present invention relates to a method of detecting the presence of Gram-negative bacteria pili in a sample.
- a diagnostic assay can be constructed by coating on a surface (i.e. a solid support) for example, a microtitration plate or a membrane (e.g. nitrocellulose membrane), antibodies specific for Gram-negative pili, and contacting it with serum or tissue sample of a person suspected of having Gram-negative bacterial infection.
- a resulting complex formed between pili in the serum and antibodies specific therefor can be detected by any of the known methods common in the art, such as fluorescent antibody spectroscopy or coiorimetry.
- the present invention relates to a diagnostic kit which contains glycosylated pili from a specific strain or species Gram-negative bacteria or several different strains and species of Gram-negative bacteria and ancillary reagents that are well known in the art and that are suitable for use in detecting the presence of antibodies to Gram-negative bacteria in serum or a tissue sample.
- Tissue samples contemplated can be monkey and human, or other mammals.
- the present invention relates to DNA or nucleotide sequences for use in detecting the presence or absence of P. aeruginosa using the polymerase chain reaction (PCR).
- the DNA sequence of the present invention can be used to design primers which specifically bind to the pilO DNA for the purpose of detecting the presence, absence, or quantitating the amount of P. earuginosa.
- the primers can be any length ranging from 7-40 nucleotides, preferably 10-15 nucleotides, most preferably 18-25 nucleotides. Reagents and controls necessary for PCR reactions are well known in the art.
- the amplified products can then be analyzed for the presence or absence of pilO sequences, for example by gel fractionation, with or without hyridization, by radiochemistry, and immunochemical techniques. This method can also be used for typing a Gram-negative bacterial infection.
- the present invention relates to a diagnostic kit which contains PCR primers specific for pilO, and ancillary reagents that are well known in the art and that are suitable for use in detecting the presence or absence of P. aeruginosa in a sample using PCR.
- Samples contemplated can be human or other mammals.
- the present invention can be used to diagnose P. aeruginosa infection by using the DNA sequences for detecting the presence or absence of pilO in genomic DNA using hybridization assays such as Southern hybridization or the expression of pilO gene by northern hybridizations and other hybridization assays well known to a person with ordinary skill in the art.
- the present invention relates to a vaccine for protection against Gram-negative bacterial infections.
- the vaccine comprises glycosylated pili, or a portion thereof, from a specific strain or species of Gram- negative bacteria or preferably, a pool of glycosylated pili from different strains or species of Gram-negative bacteria to be used as a multivalent vaccine.
- the vaccine can be prepared by inducing expression of a recombinant expression vector comprising pilA and pilO in a Gram-negative host(s) and purifying the glycosylated pili described above.
- the purified solution is prepared for administration to mammals by methods known in the art, which can include filtering to sterilize the solution, diluting the solution, adding an adjuvant and stabilizing the solution.
- the vaccine can be lyophilized to produce a vaccine against Gram-negative bacteria in a dried form for ease in transportation and storage.
- the vaccine may be prepared in the form of a mixed vaccine which contains the glycosylated pili described above and at least one other antigen as long as the added antigen does not interfere with the effectiveness of the vaccine and the side effects and adverse reactions are not increased additively or synergistically.
- the vaccine may be stored in a sealed vial, ampule or the like.
- the present vaccine can generally be administered in the form of a liquid or suspension.
- the vaccine is dissolved or suspended in sterilized distilled water before administration.
- the vaccine may be administered orally, subcutaneously, intradermally or intramuscularly but preferably intranasally in a dose effective for the production of neutralizing antibody and protection from infection or disease.
- the present invention relates to a method of reducing Gram-negative bacterial infection symptoms in a patient by administering to said patient an effective amount of anti-pili or anti-glycosylated pili antibodies, or pili (glycosylated or unglycosylated) as described above, or other agents capable of blocking pili function. Since glycosylated pili are involved in adhesion of bacteria to host cells, inhibiting or reversing the adhesion of bacteria may reduce or eliminate the development of Gram-negative bacterial infections.
- the dosage of administered agent will vary depending upon such factors as the patient's age, weight, height, sex, general medical condition, previous medical history, etc. In general, it is desirable to provide the recipient with a dosage of the above compounds which is in the range of from about lpg/kg to 10 mg/kg (body weight of patient), although a lower or higher dosage may be administered.
- the present invention provides a method for large scale production of pili. Pure, undenatured pili in milligram quantities are required for vaccine use.
- the present invention provides immunogenic epitopes from the pilA structural pilin gene representing possible glycosylation recognition sequences. These epitopes were mapped by standard peptide mapping techniques. These epitopes include the amino acid sequences designated SEQ LD NO:3 and SEQ LD NO:4. These peptides can be generated in any manner, including for example, chemical synthesis, or expression of a recombinant expression system.
- the polypeptide can be fused to other proteins or polypeptides which increase its antigenicity, such as adjuvants for example, thereby producing higher liters of anti-pilin antibodies for protection against P.aeruginosa infection.
- these peptides may be used with or without glycosylation as a vaccine or for the production of antibodies which can then be used to generate passive immunity against P. aeruginosa infection.
- strain 1244 peptide sequence conferring glycosylation can be inco ⁇ orated into other P. aeruginosa cell surface proteins of potential vaccine value using standard recombinant DNA methodologies.
- cell surface proteins include flagella and outer membrane proteins such as F and P.
- This recognition sequence could be likewise inco ⁇ orated into surface proteins of vaccine potential from other bacteria such as Bordetella pertussis, Francisella species, Neisseria meningiditis, Neisseria gonorrhoeae, Vibrio cholerae, Brucella species, certain strains of Escherichia coli, and Yersinia species. Expression of pilO from a plasmid in such an organism would result in the addition of the organisms specific O-antigen to this protein.
- P. aeruginosa 1244 a clinical isolate which has been used in pilus-mediated adhesion studies (Ramphal et al, 1984, Infect. Immun. 44: 38-40), was provided by A.T. McManus, U.S. Army Institute of Surgical Research, San Antonio, Texas.
- P. aeruginosa strain I244N3 a mutant which is unable to make pili or produce pilin (Ramphal et. al, 1991, Infect. Immun. 59: 1307-131 1) due to an inactivated rpoN gene, was furnished by S. Lory, University of Washington. Cultures were grown on LB medium (Sambrook et al., 1989, Molecular Cloning: a Laboratory Manual, vol. 1, 2nd edn. Cold Spring Harbor, N.Y.:
- Antibiotic concentrations in selective media used for P. aeruginosa were as follows: carbenicillin (Cb), 500 ⁇ g ml-'; tetracycline (Tc), 50 ⁇ g ml "1 .
- Antibiotics used with E. coli were: ampicillin (Ap), 75 ⁇ g ml "1 ; spectinomycin (Sp), 25 ⁇ g ml "1 ; tetracycline (Tc), 10 ⁇ g ml " '. Nucleotide sequencing. The Sanger dideoxy method (Sanger et al, 1977, Proc. Natl. Acad. Sci. USA 74: 5463-5467) was used.
- the template was single-stranded M 13 subclones of phage Lambda or plasmid clones (Castric et al., 1989, Mol. & Gen. Genet. 216: 75-80) containing DNA downstream from the pilA gene. Synthetic primers, derived from known sequences, or universal primers were employed.
- Plasmid constructs The plasmid pPAC46, which contained both pilA and pilO, was constructed by ligating the Sphl-HindUI plasmid fragment containing the pilA and adjacent DNA (Fig. 2) of pPAC202 (Castric et al., 1989, supra) to plasmid pUC 18 digested with these same enzymes.
- the EcoRI-H ndi ⁇ fragment of this construct, pPAC124 was ligated with the broad host range expression vector pMMB66E ⁇ (Ap r , lacP; Furste et al, 1986, supra) which had been digested with the same restriction enzymes.
- Plasmid pPAC24 which contained pilA, but not pilO, was constructed by ligating the pPAC 124 EcoK -Nhel fragment containing the pilA gene with pUC 19 digested with EcoRI and Xbal. The EcoRI-H dlll fragment of this construct, which contained only the pilA gene, was ligated with pMMB66E ⁇ digested with the same restriction enzymes. The pilA gene of both pPAC24 and pPAC46 was under control of the vector tac promoter. Since the Sphl site used in plasmid construction is located within the pilA promoter neither pPAC24 nor pPAC46 were able to express the pilin structural gene using the P. aeruginosa promoter.
- Plasmid DNA was introduced into E. coli by transformation (Sambrook et al., 1989, supra), and was transferred to P. aeruginosa by triparental mating (Ruvkun & Ausubel, 1981, Nature 289: 65-88).
- Northern blot analysis RNA was extracted as described by Reddy ( 1989, In Current Protocols in Molecular Biology, vol. 1 , 4.4.1.-4.4.7. Edited by F. M. Ausubel et al. New York: John Wiley) and separated by formaldehyde-agarose gel electrophoresis, stained with ethidium bromide, and transferred to nitrocellulose paper by capillary blot as described by Sambrook et al., (1989, supra).
- Probe DNA isolated from pPAC24 or pPAC46, was labelled by nick translation using [ ⁇ - 12 P] dCTP. Prehybridization, hybridization, and washing steps were as described by Sambrook et al., 1989. Detection of hybridization was by autoradiography. Densitometric scanning was carried out using an LKB Ultroscan laser densitometer.
- the pili remaining in the supernatant fluid were purified by a variation of the method of Silipigni-Fusco (1987, Studies in the role of somatic pili as virulence and immunity factors in the pathogenicity of Pseudomonas aeruginosa. Ph.D. thesis, University of Pittsburgh, USA). In this procedure the supernatant fluid was made 0.1 M with respect to MgCl 2 , and stored on ice for 60 min. The resulting precipitate, which contained the pilus fibres, was removed by centrifugation at 12,000 g f or 15 min.
- Pilin analysis N-terminal amino acid sequence analysis and amino acid analysis was performed on purified pilin from strain 1244N3(pPAC24). This protein was subjected to PAGE (15%T) which was followed by electroblotting to polyvinylidene difluoride paper. Preliminary staining showed that pilin was the major protein present and that it was well separated from the minor contaminants present. Pilin bands were excised and subjected to gas- phase sequencing and to amino acid analysis (University of Pittsburgh Peptide Facility).
- Pilin immunoblot analysis Pilins were separated by PAGE ( 12.5%T in the presence of either 0.1 % SDS at 5°C or 30.0 mM octyl glucoside at 15°C) or subjected to isoelectric focusing (pH 3.0 to 9.5) in the presence of 30.0 mM octyl glucoside at 15°C using the LKB-Pharmacia Phastsystem. Proteins were transferred to nitrocellulose paper by diffusion blotting; pilin adsorbed to the paper was detected using anti-pilin monoclonal antibody 6-45 (Saiman et al., 1989, Immun. 57: 2764-2770) as previously described (Castric et al., 1989, supra). The presence of pilin-bound sugar residues was detected by first derivatizing purified pili using the DIG Glycan Detection kit of
- Electron microscopy Cells to be analyzed by electron microscopy were grown on LB agar plates at 37°C for approximately eighteen hours and suspended in phosphate buffered saline. The cells were coated on 200 mesh formvar-coated copper grids, subjected to staining with 1 % uranyl acetate, and viewed in a Philips 201 electron microscope.
- the phage sensitivity test was performed by streaking a loop of pilus- specific phage PE69 on an LB agar plate. This was cross-streaked with diluted P. aeruginosa 1244 strains to be tested. Phage sensitivity was inte ⁇ reted from the absence of growth at the cross-streak junction. Twitching (Henrichsen, 1983, Annu. Rev. Microbiol. 37: 81-93) was determined by streaking strains of interest on a well dried LB agar plate where motility was scored as spreading growth at between 48 and 72 hours at 37°C. EXAMPLE 1
- the nucleotide sequence downstream from the P. aeruginosa strain 1244 pilA gene contains a potential transcriptional termination structure situated between positions 626 to 708 (noted previously in Castric et al., 1989, supra).
- a ribosome-binding site (GGAG) is seen at position 717 followed closely by three start codons, the first of which is located immediately in frame with a stop codon (TGA).
- TGA stop codon
- the second and third, GTG and ATG are in frame with each other and begin an open reading frame (referred to hereafter as pilO) which extends 1383 base pairs, using the ATG codon, to position 21 14. Codon usage of the 461 codons of the pilO gene is consistent with that of most other P.
- aeruginosa genes West & Iglewski, 1988, Nucleic Acids Res. 16: 9323-9335.
- significant differences are seen when it is compared with the adjacent pilA gene or with the pilA genes of other P. aeruginosa strains (West & Iglewski, 1988, supra; Castric & Deal, 1994, supra).
- TTT and TTC have frequencies of 20/29 and 9/29, respectively, in the pilA gene, these codons occur at rates of 6/25 and 19/25, respectively, in the pilO gene.
- the arg codons, CGT and GCG appear at rates of 26/31 and 2/31 in the pilA gene, but occur at rates of 7/31 and 1 1/31, respectively, in the pilO gene.
- the G+C% content of pilO (60.1%) is consistent with the general range given for P. aeruginosa chromosomal DNA (West & Iglewski, 1988), but quite different from the value of 52.2% determined for the strain 1244 pilA gene.
- a search of the Genbank database revealed no sequences with significant homology to the pilO gene.
- a tRNA u,r gene which contains an anticodon recognizing the rare codon ACG, can be seen just downstream of the pilO gene between positions 2166 and 2241, and is followed, between positions 2245 and 2282, by a potentially bidirectional transcriptional stop containing a 17 bp loop stem.
- a tRNA gene and transcriptional stop region have been noted previously (Hobbs et al, 1988, Gene 62: 219-227) as occurring immediately downstream from the P. aeruginosa strain PAK pilA gene, and may also be seen in the analogous region of the pilA genes of P. aeruginosa strains PAO and PA 103 (Johnson et al., 1986, supra).
- a homology comparison (Fig.
- RNA 2 RNA 1
- RNA 1 RNA 2200 base
- the smaller transcript was present in approximately a 100-fold excess over the larger mRNA as determined by densitometric scanning.
- the transcription startpoint may be presumed to begin between positions 150 and 160, suggesting that the larger transcript extends into the pilO region.
- the intermediate-sized RNA fragments might be formed by early termination, due to the loop structure referred to earlier, or might be degradation products of the larger species.
- Probe 2 which was composed of pilO DNA, hybridized only with the larger fragment and the intermediate pieces suggesting that the origin of the 2200 base mRNA is in the pilA region and that synthesis of this molecule extends downstream through the pilO gene. This was confirmed by the reaction of probe 3 which was composed of DNA from the latter part of the pilO gene and the tRNA-transcriptional stop region. This probe hybridized with the larger fragment but with neither the pilA transcript nor the intermediate fragments. This probe also hybridized with a very small RNA population, presumably tRNA produced by the p /0-associated gene as well as with cross-reacting species. Overall these results indicate that pilA, pilO and probably the adjacent tRNA gene are part of a single transcriptional unit which utilizes the pilA promoter.
- Fig. 4 shows that pilin from strain 1244N3(pPAC46) reacted with this antibody indicating the presence of sugar moieties, while pilin from strain 1244N3(pPAC24) gave no reaction.
- Pili were dissociated into pilin monomers and dimers in the presence of 30.0 mM octyl glucoside (Watts et al, 1982a, Can. J. Biochem. 60: 867-872; Watts et al, 1982b, /. Bacteriol. 151: 1508-1513; Watts et al, 1983, Biochemistry 22: 687-691), subjected to isoelectric focusing, then blotted to nitrocellulose paper, and probed with pilin-specific monoclonal antibodies.
- the pi of mature strain 1244 pilin is predicted from the pilA gene sequence (assuming that the amino-terminus is blocked and the two cysteines form a disulfide) to be 7.00.
- I244N3(pPAC46) also focused at pH 4.75 in the presence of 8.0 M urea and 2.5% (v/v) Triton X-100 (results not shown).
- Pilin preparations from strain 1244N3(pPAC46) or the wild-type strain contained trace amounts of the neutral pilin form (results not shown) possibly due to chemical or enzymatic action.
- Carbenicillin 200 ⁇ g/ml], Tetracyline [50 ⁇ g/ml], and isopropyl thiogalactoside [IPTG, 5 mM] was inoculated with 25 ml of an overnight culture of Pseudomonas aeruginosa 1244N3(pPAC46) grown with the same medium (minus the IPTG). This host strain is RpoN " .
- the inoculated medium was incubated at 37C with rotary agitation 250 ⁇ m for 7 hours.
- the overnight starter culture was grown under the same conditions in a 125 ml Erlenmyer flask.
- This material was suspended with 50 ml 10.0 mM Tris/HCl, pH 7.6 containing 20% sucrose and centrifuged (4,200 xg for 15 min). The precipitate was discarded and the supernatant fluid was reprecipitated with PEG and MgCl 2 as described above, and stored overnight at 4C. The light grey-tan precipitate (containing the pili) was removed by centrifugation (13,200 x g for 30 min) and suspended with 25 ml 10.0 mM Tris/HCl, pH 7.6 containing 20% sucrose.
- ICR mice 25-30 g were immunized with P. aeruginosa strain 1244 pili at a concentration of 5 mg/mouse/dose diluted in physiologic saline.
- the following immunization schedules were used to determine antibody response: i.n./i.n., s.c./s.c, i.p. .p., i.n./s.c, s.cJi.n., i.n./i.p., i.p./i.n..
- the time interval between the doses was 7 days.
- mice were anesthetized i.p.
- mice were sacrificed by CO 2 inhalation to obtain serum samples via cardiac puncture as well as bronchoalveolar lavage (BAL) samples for antibody titers.
- BAL samples lungs were washed once with 1 ml of sterile physiologic saline via a 25 G hypodermic needle inserted into the trachea.
- Antibody titers were determined by means of an ELISA using 96-well plates coated with P. aeruginosa 1244 pili at a concentration of 2 mg/ml (50 ml well, 4 ° C, over night [O/N]). After blocking and washing, samples were serially diluted (2-fold) in duplicate in blocking buffer and incubated O/N at 4 ° C.
- Bound antibodies were detected using goat-anti-mouse-IgG/alkaline phosphatase labelled, goat-anti-mouse-IgM/alkaline phosphatase labelled, and goat-anti-mouse-IgA/alkaline phosphatase labelled (Incubation O/N, 4 C); plates were developed with p-Nitrophenylphosphate in diethanolamine buffer and read in a Biotek ® Ceres 900 C ELISA reader. ELISA titers are defined as log 10 of the dilution which gave a change of A ⁇ of 0.200 after 30 min.
- P. aeruginosa 1244 was grown to mid-log phase in trypticase soy broth for 4 h at 37 ° C. After washing the bacteria with physiologic saline, the OD 650 was adjusted to 0.480 which corresponded to an estimated CFU count of 2 x lOVml.
- Mice were challenged i.n. using 2 different doses (LD I00 , LD 5 ) at day +7 after the second dose of pili. Anesthesia was done as described above, and bacteria were delivered in a final volume of 50 ml. Mortality and body weight were monitored daily for 14 days. Control mice received physiologic saline only. Time to recovery in sublethal challenge experiments was defined as number of days until the baseline body weight was regained or (if animals did not reach their baseline body weight) as number of days until stabilization of body weight (3 consecutive days with weight change
- mice All data are medians (not means) from 3 mice. They represent the log l0 of 10-fold dilutions which gave a change of A 4I0 of 0.200/15 min.
- the antigenicity of the pilin glycan was studied.
- the isolated glycan competes with pure pili (Fig 7) for reaction with monoclonal 1 1.14 (an antibody which reacts with both strain 1244 LPS and pili).
- monoclonal 1 1.14 an antibody which reacts with both strain 1244 LPS and pili.
- These results show that pilin glycans are relatively small (probably mono and di-saccharides). Small size indicates that (since glycosylation appears to change the pilin molecular weight by a value of 1200) several copies of these glycans exist on the pilus surface.
- a certain amount of heterogeneity among the glycans is likely and the pilin glycan contains an epitope which is also found on the strain 1244
- the plasmids described above (which contain either the pilA gene alone (pPAC24) or both the pilA and pilO genes (pPAC46) can easily be moved (by conjugal mating) into various P. aeruginosa strains where these pilin genes can be expressed through IPTG stimulation of the tac promoter.
- the 1244 pilin produced had the apparent molecular weight predicted by the gene structure.
- the 1244 pilin produced appeared to be modified as indicated by apparent molecular weight. If these modified pilins contain glycan composed of host cell LPS O-antigen building blocks it is potentially possible to detect this material using O-antigen type- specific antisera. Experiments exploring this possibility are as follows.
- Pilin produced from plate cultures (grown in the presence of IPTG) was subjected to isoelectric focusing, followed by diffusion blotting to PVDF paper. These blots were then probed with monoclonal antibodies giving the results seen in Table 8 (numbers in parentheses are approximate pi's).
- Vaccine design requires knowledge of epitope structure. While B- and T-cell epitopes of P. aeruginosa PAO and PAK pili have been determined in general terms (Watt, et al, 1983, Infect. Immun. 42: 1 13-121 ; Sastry et al, 1985, Can. J. Biochem. Cell. Biol. 63: 284-291), nothing is known of the common pilus type produced by strain 1244. Analysis of this pilus was carried out using the Geysen test (Carter, 1994, In: Methods in Molecular Biology.
- Regions 1 and 4 were determined to be immunodominant based on frequency and intensity of reaction. Since the anti-pilus sera were raised against native pi these epitope regions represent portions of the pilin primary structure which occupy the pilus fiber surface, and so are key targets m peptide vaccine design.
- a peptide In order for a peptide to provide a protective response it must occupy a part of the pilus surface which is involved in the two activities of the pilus c ⁇ tical to pathogenesis: a)adhesion tothe host cell, and b) retraction of the pilus fiber (which insures locking on of the pathogen to the host cell surface) Since both activities are required for colonization and, interference of either by the immune response would be protective. Since region 1 (SEQ LD NO: 5) is a potential protective epitope, it is important to note that it contains a sequence (LKT--E) common to most P. aeruginosa pilins (Cast ⁇ c and Deal, 1994, supra).
- Anti- 1244 pilus monoclonal 5.44 also maps to this region (Castric and Deal, 1994, supra). This monoclonal reacts (Western blot) with pilins from strains which only contain this sequence similarity indicating that these residues form the core of this epitope region.
- the carboxy-proximal portion, roughly analogous to region 4 of 1244 pilin, of the strain PAO and PAK pilins house the host receptor binding site (Lee et al. , 1989, Molec. Microbiol 3: 1493-1499; Doig et al. ,1989, Can. J. Microbio 35: 1141-1 145; Doig et al ,1990, Infect. Immun. 58: 124-130).
- Anti- 1244 pilus monoclonal 6.45 maps to region 4 of 1244 pilin [Cast ⁇ c and Deal, 1994, supra] and blocks adhesion to bovine tracheal cells (Saiman et al. ,1990, J. Infect. Dis. 161:541-548) indicating that region 4 contains the host binding site and so is a prime vaccine target.
- results presented in this paper suggest that pilin from P. aeruginosa 1244 also is glycosylated.
- the composition of the pilin-associated material remains to be determined, however several candidates, including the acidic moieties of the lipopolysaccharide core, alginic acid subunits, as well as other acidic elements or phosphoryiated compounds, must be considered.
- Limitations of SDS-PAGE prevent reliable molecular weight determinations of glycosylated proteins, a test which must await the use of a more accurate technique such as mass spectrometry.
- Linkage of glycosylated proteins is usually via the reducing end of an oligosaccharide sugar through an O- or N-linkage to the hydroxyl group of serine (or threonine) or the amide group of asparagine (Montreuil et al, 1986, In Carbohydrate Analysis, a Practical Approach, pp. 143-204. Edited by M. F. Chaplin & J. F. Kennedy. Oxford: LRL Press).
- the residues in the region of N-linked moieties have the characteristic consenus sequence N-X-S (or T). While this sequence may be found in the N. meningitidis pilin primary structure (Virji et al, 1993), it is absent in P. aeruginosa strain 1244 pilin, suggesting the presence of an N- linkage, a different sequence specificity, or the utilization of an alternative method of attachment.
- N-X-S or T
- pili from P. aeruginosa strains PAO and PAK contained no sugar residues. Since the primary structure of pili from strain 1244 is distinctive when compared to those of strains PAO and PAK (Castric & Deal, 1994), pilus modification may represent a strain difference. P. aeruginosa strains producing pili antigenically related to those of strain 1244 are common among clinical isolates (Castric & Deal, 1994). Thus, pilin glycosylation by this bacterium could be useful in clinical identification. Likewise, demonstration of the presence of the pilO gene could be of diagnostic value.
- pili Specific recognition by the pili allows attachment of the pathogen to host cells containing the proper receptors (Baker, 1993, In Pseudomonas aeruginosa. the Opportunist: Pathogenesis and Disease, pp. 7-24. Edited by R. B. Fick. Boca Raton: CRC Press; Heckels etal, 1976).
- the acidic modification might stabilize this attachment through the formation of salt bridges once specific binding had occurred.
- pilin glycosylation may be involved in specific or nonspecific adhesion to the host cell which is independent of pilin protein-mediated attachment. Adhesion studies utilizing PilO * and PilO " variants of P. aeruginosa strain 1244, as well as glycosylated and nonglycosylated pili, will be required to clarify these points.
- pilO gene is part of the pilA transcriptional unit.
- the pilA and pilO genes, along with a tRNA thr gene, are present in the form of an operon, two major transcription products are generated (an individual pilA message and a pilA/pilO/tRNA"" transcript) which are present in a ratio of about one hundred to one.
- pilin is a major cell protein, while PilO would likely be required in only catalytic or regulatory amounts.
- the difference in transcription levels could be the result of premature termination of message synthesis or relative instability of the transcript corresponding to the pilO region.
- the role of translation efficiency should also be considered a factor in differential gene expression since the beginning of the pilO message contains a short loop region which includes the start codon.
- Such a structure has been suggested to be able to significantly reduce translation (Gold, 1988, Annu. Rev. Biochem. 57: 199- 233), and may function to further control expression of a gene coding for a product required in small amounts when it shares a promoter with a gene coding for a product needed in large amounts.
- the pilO gene product is predicted to code for a protein with a molecular weight of 50.862 using as start codon the ATG beginning at position 729 (Fig. 1 ).
- Hydropathy profile (Kyte & Doolittle, 1982, J. Mol Biol 157: 105-132) of the primary structure indicates that PilO contains nine hydrophobic regions which are flanked by clusters of charged residues.
- Secondary structure prediction (Chou & Fassman, 1974, Biochemistry 13: 21 1-221) suggests that large portions of these hydrophobic regions are composed of ⁇ -structure which are of adequate length to span the 3.0 nm membrane lipid core.
Abstract
The present invention relates to a broadly reactive vaccine against Gram-negative bacteria which is composed of a biological glycan-pilus sonjugate. The conjugate core is a common pilus type to which is attached the glycan of choice in vivo. Pooling of these bioconjugates produces a multivalent vaccine. These pili give high bronchial titers when delivered by the intranasal route. Mice vaccinated with pure glycosylated P. aeruginosa strain 1244 pili in this manner are protected against respiratory challenge with P. aeruginosa strain 1244. The present invention further relates to a DNA and amino acid sequence of a new gene, pilO, which is capable of glycosylating pilin of Gram-negative bacteria and uses thereof.
Description
TITLE OF THE INVENTION
A Conjugate Vaccine Against Gram-Negative Bacterial Infections
INTRODUCTION
Pseudomonas aeruginosa is recognized as a leading cause of life- threatening infection among compromised patient populations in hospitals. Cancer patients, and patients with burn wounds, cystic fibrosis, acute leukemia, organ transplants, and intravenous-drug addiction are particularly susceptible to acquiring a serious P. aeruginosa infection. The most serious infections include pneumonia, septicemia, malignant-external otitis, and meningitis. The mortality rate for such infections can exceed 50%, and is usually the highest for any bacterial pathogen (Cryz, S. J., Jr. In Pseudomonas aeruginosa as an Opporunistic Pathogen. Mario Campa et al., Eds. Plenum Press, New York, 1993, pp. 383-395. All documents cited herein infra and supra are hereby incorporated by reference thereto).
Therapy for the management of severe P. aeruginosa infections has been a problem for many years due to the debilitated condition of the patient and the high frequency of multiple antibiotic resistance of clinical isolates of this bacteria. Immunotherapy has been explored as an alternative. In this area, attention has focused on the virulence factors of P. aeruginosa. As with other bacterial pathogens, virulence of P. aeruginosa is multifactorial and is the product of many interacting factors involving both the bacterium and the human host. P. aeruginosa is an opportunistic pathogen, therefore, a key component of this bacterium's pathogenicity is the ability of the microorganisms to adhere to epithelial cells of mucosal surfaces (E. H. Blackey, 1981, J Infect. Dis. 143: 325-345). The somatic pili of P. aeruginosa, protein filaments clustered around the flagellum and extending from the cell surface, have been implicated in adherence to host tissue (Ramphal et al., 1984, Infect. Immun. 44: 38-40; Woods et al., 1980, Infect. Immun. 29: 1 146-1 151). Pili are composed of
monomeric subunits. pilin, which have a molecular weight of 15-18000 daltons (Frost and Paranchych, 1977, J. Bacteriol.131 : 259-269; Sastry et al. , 1983, FEBS Lett 151:253-256; Sastry et al. .1985, J. Bacteriol. 164:571-577) and are arranged in a helical fashion within the pilus fiber (Watts et al. .1983, Biochemistry 22: 3640-3646). The pilins of P. aeruginosa are similar in structure and function to those produced by many Gram-negative bacteria such as species of the genera Dichelobacter (Elleman, T. C. 1988 Microbiol. Rev. 52:233-247), Eikenella (Rao and Progulske-Fox, 1993 J. Gen. Microbiol. 139: 651-660), Kingella (Weir and Marrs, 1992, Infect. Immun. 60: 3437- 3441 ), Moraxella (Marrs et al. 1985, J. Bacteriol. 163: 132-139), Neisseria (Meyer et al., 1984, Proc. Natl. Acad. Sci. USA 81: 61 10-61 14), and Vibrio (Faast et al., 1989, Gene 85: 227-231).
In P. aeruginosa, pilin is encoded by a single chromosomal copy (Pasloske et al., 1985, FEBS Lett. 183: 408-412; Sastry et al., 1985, J. Bacteriol. 164: 571-577), the pilA gene. The nucleotide sequence of several P. aeruginosa pilA genes is known and comparisons of deduced pilin primary structure and flanking DNA sequence have shown characteristic variation which allows differentiation of P. aeruginosa pilins into at least two groups, group I (such as pili strain 1244) and group II pilins (PA103, T2A, PAO, PAK pilins) (Castric and Deal, 1994, Infect. Immun. 62: 371-376). This pilus grouping is further supported by nucleotide sequence homology of the regions flanking the pilA gene. A surprising feature of this work was the discovery that group I pilin determinants were relatively common (58/95 and include different strains of different immunotypes as determined by polyclonal antibody reaction) among clinical isolates. These results indicate that group I pili represent a major clinical serogroup from which potential components of an anti-pilus vaccine with broad specificity may be obtained.
The use of P. aeruginosa pili as a vaccine presents many advantages. Unlike previous lipopolysaccharide-based Pseudomonas vaccines, pili produce minimal side effects and are well known to be immunogenic in humans, possibly due to antigen organization (Bachman, et al. ,1993, Science 262: 1448-1451) brought about by subunit arrangement in the fiber. Much is known of the biochemistry and molecular biology of the pili and the technology is available for the identification and characterization of pilus epitopes. Pili can be prepared easily in homogeneous form and methods described in this application
allow large scale production of pili which are compatible with modern forms of vaccine delivery such as microencapsulation. The P. aeruginosa pili can be engineered to act as "carriers" for other protein epitopes. thereby conferring the advantages of pili to other antigens; DNA sequences coding for known protein epitopes (outer membrane proteins for example) could be used to replace known surface pilin epitopes by PCR methodologies. The advantages of peptide technology can be applied to pilus vaccines. Cocktails of peptide epitopes can be constructed to deal with antigenic variation seen in serotype populations.
SUMMARY OF THE INVENTION
The present invention relates to a pilus-based vaccine and is based on recent work showing that pili from group I strains of P. aeruginosa, a clinically common group, are glycosylated and that pili glycosylation may be involved in specific or nonspecific adhesion to the host cell independent of pilin protein- mediated attachment (Castric, P. , 1995, Microbiology 141: 1247- 1254).
Glycosylated pili are shown to produce high bronchial titers when delivered by the intranasal route. Mice vaccinated with pure P. aeruginosa strain 1244 pili in this manner are protected against respiratory challenge with P. aeruginosa strain 1244. More specifically, the present invention relates to a new gene sequence, pilO, the product of which glycosylates the pili of P. aeruginosa strains by adding the specific O-antigen components of the lipopolysaccharide (LPS) carried by that strain onto the pili resulting in antigenic glycosylated pili useful as a vaccine against infection with that strain. Nucleotide sequencing of a region downstream from the pilin structural gene (pilA) of P. aeruginosa strain 1244 (a group I strain), revealed an open reading frame (ORF) potentially able to code for another protein. This ORF, called pilO, was flanked by a tRNAlhr gene, which was followed by a transcriptional termination sequence. The tRNAthr gene and the termination sequence were nearly identical to sequences found immediately adjacent to the pilA gene of several P. aeruginosa strains. A 2200 base mRNA strand, which contained both the pilO and pilA transcripts, was prodcuced from this region, while a 650 base transcript containing only pilA was present in a 100- fold excess over the longer transcript. Hyperexpression of the pilA gene in a pilO' strain resulted in normal pilus-specific phage sensitivity and twitching motility,
two other functions of pili. The pilin produced by this strain however had a lower apparent Mr and a more neutral pi compared to that produced by a strain containing a functional pilO gene. This pilin failed to react with a sugar-specific reagent which recognized pilin produced by the strain containing a functional pilO gene (Castric, P., 1995, Microbiology 141 : 1247- 1254).
Experiments have shown that pilO is specific for strain 1244 pilin. For example, strain 1244 will produce strain PA 103 pili (a group II pilin) from a plasmid carrying the cloned gene, but will not glycosylate the PA 103 pilin protein. However, pilO is not specific for the O-antigen attached to the strain 1244 pilin. pilO will glycosylate strain 1244 pili with the LPS O-antigen repeating units of other P. aeruginosa strains. For example, strain PAK (another group II strain), carrying a plasmid retaining both the pilO gene and strain 1244 pilin gene, will produce strain 1244 pili carrying the chemically and serologically distinctive strain PAK O-antigen. In fact, the potential for O- antigen range of glycosylation is extremely wide and can extend to virtually any Gram-negative bacterium, P. aeruginosa and other species.
The recent discovery of pilin glycosylation allows the design of vaccines specific for different strains of P. aeruginosa, or of Gram-negative bacteria, by the addition to the pilin core of the specific glycan produced in the bacteria for which a vaccine is desired and using the resulting pili as a vaccine. Other vaccines presently being studied are composed of the LPS associated with the O-antigen. The use of an LPS based vaccine has several serious drawbacks as compared to the use of glycosylated pili as a vaccine. Glycosylated pili contain the immunogenic portion (O-antigen) but not the toxic part (lipid A) of the LPS molecule resulting in a safer, better tolerated vaccine. The range of protection of a cocktail of glycosylated pili will be broader than a cocktail of LPS due to the common epitopes of the pilus protein. Protection will be both pilus based and O-antigen based. LPS purification is time consuming, expensive and difficult. Glycosylated pili can be produced in large amounts by a new method described in this application involving the use of broth cultures instead of the commonly used agar cultures. Purification of glycosylated pili is quickly accomplished, inexpensive, and requires only common laboratory procedures.
The design of a pilus vaccine and understanding the immunological relationship among native pili is dependent on the ability to determine which parts of the pilus surface make up the B-cell epitopes. The positions of the
protein B-cell epitopes of the native strain 1244 pili were determined using the Geysen tethered peptide pin assay as described in Castric and Deal, 1994, supra. Four epitope regions were revealed representing the portions of the piiin primary structure which occupy the surface of the pilus fiber. These sequences would be important in peptide vaccine design. Two of these sequences, region 3 (SEQ LD NO: 3) and region 4 (SEQ ID NO: 4) may also represent glycosylation recognition sequences according to recent results from peptide mapping of PilA.
Therefore, it is an object of the present invention to provide a pilO DNA fragment encoding 1386 nucleotides useful as a glycosylation sequence for 1244 pilin protein in the production of a diagnostic agent and a vaccine.
It is another object of the present invention to provide a pilO DNA fragment useful as a glycosylation sequence for pilin of other gram negative bacteria. The pilO protein is capable of glycosylating any protein which contains the pilin glycosylation recognition sequence. The sequence can be incoφorated in several ways, for example, using PCR methods, the pilin glycosylation recognition sequence can be inserted into a gene of a known surface protein; this engineered gene can be incoφorated into the chromosome of the host by gene replacement, and pilO hyperexpressed from a broad host range plasmid such as pPAC46 which grows and functions in nearly all Gram- negative bacteria.
It is another object of the present invention to provide an amino acid sequence for pilO protein encoding 461 amino acids.
It is another object of the invention to provide a recombinant vector comprising a vector and the above described DNA fragment.
It is another object of the invention to provide a recombinant vector comprising a vector and the above described DNA fragment functionally positioned next to a pilin gene, preferably the pilin gene of strain 1244.
It is a further object of the present invention to provide a host cell transformed with any of the above-described recombinant DNA constructs.
It is another object of the present invention to provide a method for producing pilO protein which comprises culturing a host cell under conditions such that a recombinant vector comprising a vector and the pilO DNA fragment
is expressed and pilO protein is thereby produced, and isolating pilO protein for use as a glycosylation agent.
It is yet a further object of the invention to provide a method for producing glycosylated pilin or a pilin-glycan conjugate which comprises culturing a host cell under conditions such that the above-described DNA fragment is expressed and glycosylated pilin is produced, and isolating glycosylated pilin for use as a vaccine and diagnostic agent.
It is still another object of the invention to provide a purified pilO protein useful as a glycosylating agent. It is a further object of the present invention to provide an antibody to the above-described glycosylated pilin for use as a therapeutic agent and a diagnostic agent.
It is yet another object of the invention to provide a P. aeruginosa vaccine comprising a pilin-glycan conjugate effective for the production of antigenic and immunogenic response resulting in the protection of a mammal against P. aeruginosa infection.
It is a further object of the invention to provide a multivalent Gram- negative vaccine comprising glycosylated pilins from a variety of strains or species of Gram-negative bacteria effective for the production of antigenic and immunogenic response resulting in the protection of a mammal against infection with Gram-negative bacilli.
It is yet another object of the present invention to provide a method for the diagnosis of P. aeruginosa infection comprising the steps of:
(i) contacting a sample from an individual suspected of having the infection with antibodies which recognize glycosylated pilin or an attached glycan of P. aeruginosa; and
(ii) detecting the presence or absence of a complex formed between P. aeruginosa and antibodies specific therefor.
It is yet another object of the present invention to provide a method for the diagnosis of Gram-negative bacterial infection comprising the steps of: (i) contacting a sample from an individual suspected of having the disease with antibodies which recognize glycosylated pilin or an attached glycan of Gram-negative bacteria; and
(ii) detecting the presence or absence of a complex formed between Gram-negative bacteria and antibodies specific therefor.
It is yet another object of the present invention to provide a method for the diagnosis of P. aeruginosa from a sample using the polymerase chain reaction, said method comprising:
(i) extracting DNA from the sample; (ii) contacting said DNA with
(a) at least four nucleotide triphosphates.
(b) a primer that hybridizes to pilO DNA, and
(c) an enzyme with polynucleotide synthetic activity, under conditions suitable for the hybridization and extension of said first primer by said enzyme, whereby a first DNA product is synthesized with said DNA as a template therefor, such that a duplex molecule is formed;
(iii) denaturing said duplex to release said first DNA product from said DNA;
(iv) contacting said first DNA product with a reaction mixture comprising:
(a) at least four nucleotide triphosphates,
(b) a second primer that hybridizes to said first DNA, and
(c) an enzyme with polynucleotide synthetic activity, under conditions suitable for the hybridization and extension of said second primer by said enzyme, whereby a second DNA product is synthesized with said first DNA as a template therefor, such that a duplex molecule is formed;
(v) denaturing said second DNA product from said first DNA product; (vi) repeating steps iii-vi for a sufficient number of times to achieve linear production of said first and second DNA products;
(vii) fractionating said first and second DNA products generated from said pilO DNA; and
(viii) detecting said fractionated products for the presence or absence of pilO in a sample. It is yet another object of the present invention to provide a method for the detection of P. aeruginosa in a sample which comprises assaying for the presence or absence of pilO RNA or DNA in a sample by hybridization assays. It is a further object of the present invention to provide a diagnostic kit comprising a glycosylated pilin antibody and ancillary reagents suitable for use in detecting the presence P. aeruginosa in mammalian tissue or serum.
It is another object of the present invention to provide a diagnostic kit comprising antibodies against glycosylated pilins of Gram-negative bacteria and ancillary reagents suitable for use in detecting the presence of Gram-negative bacteria in mammalian tissue of serum. It is a further object of the present invention to provide a diagnostic kit comprising primers specific for the amplification of pilO sequences and ancillary reagents suitable for use in detecting the presence P. aeruginosa in mammalian tissue or serum.
It is yet an object of the present invention to provide a therapeutic method for the treatment or amelioration of symptoms of P. aeruginosa and other species of Gram-negative bacilli, said method comprising providing to an animal or individual in need of such treatment an effective amount of sera from individuals immunized with one or more pilin-glycan conjugate(s) in a pharmaceutically acceptable excipient. It is further another object of the present invention to provide a therapeutic method for the treatment or amelioration of symptoms of Gram- negative infection, said method comprising providing to an individual in need of such treatment an effective amount of antibodies against the pilin-glycan conjugate or attached glycan of the Gram-negative bacteria thereby inhibiting the adhesion and colonization of the bacteria in the host in a pharmaceutically acceptable excipient.
It is another object of the present invention to provide a therapeutic method for the treatment or amelioration of symptoms of Gram-negative infection, said method comprising providing to an individual in need of such treatment an effective amount of glycosylated pili from a variety of strains or species of Gram-negative bacteria in order to inhibit adhesion of bacteria to a host cell.
It is yet another object of the present invention to provide a method for large scale production of pilin, either glycosylated or ungiycosylated, for use as a vaccine and a diagnostic agent.
It is still another object of the present invention to provide antigenic epitopes of pilA, the pilin core protein, which are useful in peptide vaccine design.
BRIEF DESCRIPTION OF THE DRAWINGS
These and other features, aspects, and advantages of the present invention will become better understood with reference to the following description and appended claims, and accompanying drawings where: Figure 1 shows sequence homology of the region downstream from the pilO gene, with the region downstream of the pilA gene of P. aeruginosa strain PA103 (Johnson et al., 1986, 7. Biol. Chem. 261: 15703-15708). Colons indicate base homology. Regions containing significant dyad symmetry are indicated by opposing arrows. The tRNA gene region is highlighted. Figure 2 shows a comparison of the pilin gene regions of P. aeruginosa strain 1244 and strain PA 103. Potential transcπptional stops are indicated by the letter "t". Restriction endonuclease sites are H, HindlLT; N, Nhel. P, Pstl; S, Sphl.
Figure 3 is a Northern blot analysis of mRNA extracted from P. aeruginosa strain 1244. A. Probes were prepared from restriction fragments of cloned DNA indicated in the Fig. 2 map as follows: Lane 1, Probe 1 (the Sphl-Nhel fragment); Lane 2, Probe 2 (the Nhel-Pstl fragment); Lane 3, Probe 3 (the Pstl-HindUl fragment). Arrows indicate positions of E. coli strain ΗB101 πbosomal RNA. B. Densitometric scan of lane 1 of panel A of this figure. Scanning was from bottom to top of the autoradiogram shown. Electrophoresis point of origin is marked by the arrow
Figure 4 shows immunodetection of electrophoretically separated P. aeruginosa pilin. A. SDS-PAGE of pilin at 5°C. Lane 1 , 3 μg pilin produced by P. aeruginosa strain 1244N3(pPAC46), Lane 2, 3 μg pilin produced by P aeruginosa strain 1244N3(pPAC24). Molecular weights are given as times
10"3. B. Isoelectric focusing of pilin at 15°C. Lane 1, 3 μg pilin produced by
P. aeruginosa strain 1244N3(pPAC24), Lane 2, 3 μg pilin produced by P. aeruginosa strain 1244N3(pPAC46). The pΗ gradient was determined by focusing pi standards on an identical gel in the absence of octyl glucoside. Figure 5 shows the detection of P. aeruginosa pilin carbohydrate by immunoblot. Lane 1 , 10 μg pilin produced by P. aeruginosa strain 1244N3(pPAC46), Lane 2, 10 μg pilin produced by P. aeruginosa strain 1244N3(pPAC24). Molecular weights are given as times 10"\ Arrows indicate
positions of these pilins on an identical blot using monoclonal antibody 6-45 for detection.
Figure 6: Gel filtration of protease digested strain 1244 pili.
Figure 7: Competition ELISA (glycan vs native pili) using monoclonal antibodies 1 1.14 and 5.44.
Figure 8: Major epitopes of P. aeruginosa 1244 pilus as determined by the Geysen pin test.
DETAILED DESCRIPTION In one embodiment, the present invention relates to a DNA or cDNA segment which encodes pilO, a glycosylation sequence of pilA pilin core protein. The sequence of the gene, specified in SEQ LD NO: 1 , was obtained by sequencing a region downstream from the P. aeruginosa 1244 pilA gene. The sequenced gene fragment comprising 1386 nucleotides of open reading frame with a 60.1 % G+C content consistent with the general range given for P. aeruginosa chromosomal DNA.
DNA or polynucleotide sequences to which the invention also relates include sequences of at least about 6 nucleotides, preferably at least about 8 nucleotides, more preferably at least about 10-12 nucleotides, most preferably at least about 15-20 nucleotides corresponding, i.e., homologous to or complementary to, a region of the pilO nucleotide sequence. Preferably, the sequence of the region from which the polynucleotide is derived is homologous to or complementary to a sequence which is unique to the pilO gene. Whether or not a sequence is unique to the pilO gene can be determined by techniques known to those of skill in the art. For example, the sequence can be compared to sequences in databanks, e.g., GenBank. Regions from which typical DNA sequences may be derived include but are not limited to, for example, regions encoding specific epitopes, as well as non-transcribed and/or non-translated regions. The derived polynucleotide is not necessarily physically derived from the nucleotide sequence shown in SEQ ID NO: 1 , but may be generated in any manner, including for example, chemical synthesis or DNA replication or reverse transcription or transcription, which are based on the information provided by the sequence of bases in the region(s) from which the polynucleotide is derived. In addition, combinations of regions corresponding
to that of the designated sequence may be modified in ways known in the art to be consistent with an intended use. The sequences of the present invention can be used in diagnostic assays such as hybridization assays and polymerase chain reaction assays and for the discovery of other pilO sequences. In another embodiment, the present invention relates to a recombinant
DNA molecule that includes a vector and a DNA sequence as described above. The vector can take the form of a plasmid such as any broad host range expression vector for example pMMB66EH and others known in the art.
In a further embodiment, the present invention relates to host cells stably transformed or transfected with the above-described recombinant DNA constructs. The host cell can be any Gram-negative bacteria for which glycosylated pilin is desired. The vector containing the pilO gene is expressed in the bacteria and the product of the pilO gene is able to add subunits of the specific O-antigen of the host bacteria to the core pilin producing glycosylated pilins which can be isolated for use as a vaccine and in diagnostic assays. For example, the plasmid pPAC46, described below in Materials and Methods, containing both the pilA and pilO wherein the pilA gene of strain 1244 was placed downstream from the tac promoter (in such a way as to inactivate the pilA promoter) of the broad host range expression vector pMMB66EH (Furste, et al, 1986, Gene 48: 1 19-131) results in high levels of glycosylated pilus production by hyper-expression of the pilA gene. Promoters other than the tac promoter include λ PL promoter, T7 promoter, and MalE promoter. Please see e.g., Maniatis, Fitsch and Sambrook, Molecular Cloning: A Laboratory Manual (1982) or DNA Cloning. Volumes I and II (D. N. Glover ed. 1985) for general cloning methods. The DNA sequence can be present in the vector operably linked to a highly purified IgG molecule, an adjuvant, a carrier, or an agent for aid in purification of glycosylated pilin. The transformed or transfected host cells can be used as a source of DNA sequences described above. When the recombinant molecule takes the form of an expression system, the transformed or transfected cells can be used as a source of the protein described below. In another embodiment, the present invention relates to a pilO protein having an amino acid sequence corresponding to SEQ LD NO: 2 and encompassing 461 amino acids or any allelic variation thereof.
A polypeptide or amino acid sequence derived from the amino acid sequence in SEQ LD NO:2, refers to a polypeptide having an amino acid sequence identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least 2-5 amino acids, and more preferably at least 8- 10 amino acids, and even more preferably at least 1 1-15 amino acids, or which is immunologically identifiable with a polypeptide encoded in the sequence.
A recombinant or derived polypeptide is not necessarily translated from a designated nucleic acid sequence, or the sequence in SEQ LD NO: 1 ; it may be generated in any manner, including for example, chemical synthesis, or expression of a recombinant expression system. In addition the polypeptide can be fused to other proteins or polypeptides for example, MalE protein for transport into the periplasm or for secretion from the cell.
In a further embodiment, the present invention relates to a method of producing glycosylated pilin which includes culturing the above-described host cells, under conditions such that the DNA fragment is expressed and a glycan specific for such host cells is added to the core pilin protein producing glycosylated pilin. The glycosylated pili can then be isolated using methodology well known in the art or by the new large scale production method described below. The glycosylated pili can be used as a vaccine for immunity against infection with the host bacteria or as a diagnostic tool for detection of host bacterial infection. The transformed host cells can be used to analyze the effectiveness of drugs and agents which inhibit adhesion of host bacteria to cells, such as host proteins or chemically derived agents or other proteins which may interact with the bacteria to down-regulate or alter the expression of pilO or affect the ability of pili to adhere to cells. A method for testing the effectiveness of a drug or agent capable of inhibiting the adhesion of the Gram-negative bacteria being studies can be for example the adhesion assay of Deal and Krivan, Met. Enzymol. 236: 346-353. In another embodiment, the present invention relates to antibodies specific for the above-described glycosylated pili. For instance, an antibody can be raised against the complete glycosylated pili or against a portion thereof. Persons with ordinary skill in the art using standard methodology can raise monoclonal and polyclonal antibodies to the pili (or polypeptide) of the present invention, or the specific O-glycan attached to the pilin, or a unique portion of
the pilin. Material and methods for producing antibodies are well known in the art (see for example Godmg, in, Monoclonal Antibodies- Pnnciples and Practice. Chapter 4, 1986). In addition, the protein or polypeptide can be fused to other proteins or polypeptides which increase its antigenicity, thereby producing higher titers of neutralizing antibody when used as a vaccine.
Examples of such proteins or polypeptides include any adjuvants or carriers safe for human use, such as aluminum hydroxide.
In a further embodiment, the present invention relates to a method of detecting the presence of Gram-negative bacterial infection or antibodies against Gram-negative bacteria in a sample. Using standard methodology well known in the art. a diagnostic assay can be constructed by coating on a surface (i.e. a solid support) for example, a microtitration plate or a membrane (e.g. nitrocellulose membrane), all or a unique portion of the glycosylated pili described above, for example the O-antigen, and contacting it with the serum of a person suspected of having a Gram-negative bacterial infection. The presence of a resulting complex formed between glycosylated pili and antibodies specific therefor in the serum can be detected by any of the known methods common in the art, such as fluorescent antibody spectroscopy or coloπmetry. This method of detection can be used, for example, for the diagnosis and typing of Gram- negative bacterial infections.
The adhesion properties of the Gram-negative bacteπa are critical to its virulence and central to the development of pathology. Consequently, the ability of an individual to reduce bactenal adhesion would determine the patient's ability to prevent infection or disease. This may take the form of antibodies which inhibit the adhesion of pili to cells; this can be measured in an assay for the detection of glycosylated pili as described below. Such assays can be used to screen individuals after receiving a Gram-negative vaccine to measure the production of protective antibodies. Another mechanism to reduce adhesion of pili to cells is by down-regulating or altering the adhesion receptors present on the cells. Glycosylated pili can be used to measure the availability of cell receptors by contacting labeled glycosylated pili to target tissue either ex vivo or in vivo and measuring the degree to which labeled pili bind to target tissue. Pili can be labeled by any detectable label known in the art such as a radionuc de, for example. In addition, pili, glycosylated or unglycosylated can be used as receptor analogs to block the adhesion receptors present on host cells, thereby
reducing or inhibiting the adhesion of bacteria to host cells. These pili can be administered in a mouthwash for example.
In yet another embodiment, the present invention relates to a method of detecting the presence of Gram-negative bacteria pili in a sample. Using standard methodology well known in the art, a diagnostic assay can be constructed by coating on a surface (i.e. a solid support) for example, a microtitration plate or a membrane (e.g. nitrocellulose membrane), antibodies specific for Gram-negative pili, and contacting it with serum or tissue sample of a person suspected of having Gram-negative bacterial infection. The presence of a resulting complex formed between pili in the serum and antibodies specific therefor can be detected by any of the known methods common in the art, such as fluorescent antibody spectroscopy or coiorimetry. This method of detection can be used, for example, for the diagnosis of Gram-negative bacterial infection or for typing the specific Gram-negative bacteria causing such an infection. In another embodiment, the present invention relates to a diagnostic kit which contains glycosylated pili from a specific strain or species Gram-negative bacteria or several different strains and species of Gram-negative bacteria and ancillary reagents that are well known in the art and that are suitable for use in detecting the presence of antibodies to Gram-negative bacteria in serum or a tissue sample. Tissue samples contemplated can be monkey and human, or other mammals.
In yet a further embodiment, the present invention relates to DNA or nucleotide sequences for use in detecting the presence or absence of P. aeruginosa using the polymerase chain reaction (PCR). The DNA sequence of the present invention can be used to design primers which specifically bind to the pilO DNA for the purpose of detecting the presence, absence, or quantitating the amount of P. earuginosa. The primers can be any length ranging from 7-40 nucleotides, preferably 10-15 nucleotides, most preferably 18-25 nucleotides. Reagents and controls necessary for PCR reactions are well known in the art. The amplified products can then be analyzed for the presence or absence of pilO sequences, for example by gel fractionation, with or without hyridization, by radiochemistry, and immunochemical techniques. This method can also be used for typing a Gram-negative bacterial infection.
In yet another embodiment, the present invention relates to a diagnostic kit which contains PCR primers specific for pilO, and ancillary reagents that are
well known in the art and that are suitable for use in detecting the presence or absence of P. aeruginosa in a sample using PCR. Samples contemplated can be human or other mammals.
In another embodiment, the present invention can be used to diagnose P. aeruginosa infection by using the DNA sequences for detecting the presence or absence of pilO in genomic DNA using hybridization assays such as Southern hybridization or the expression of pilO gene by northern hybridizations and other hybridization assays well known to a person with ordinary skill in the art. In another embodiment, the present invention relates to a vaccine for protection against Gram-negative bacterial infections. The vaccine comprises glycosylated pili, or a portion thereof, from a specific strain or species of Gram- negative bacteria or preferably, a pool of glycosylated pili from different strains or species of Gram-negative bacteria to be used as a multivalent vaccine. The vaccine can be prepared by inducing expression of a recombinant expression vector comprising pilA and pilO in a Gram-negative host(s) and purifying the glycosylated pili described above. The purified solution is prepared for administration to mammals by methods known in the art, which can include filtering to sterilize the solution, diluting the solution, adding an adjuvant and stabilizing the solution. The vaccine can be lyophilized to produce a vaccine against Gram-negative bacteria in a dried form for ease in transportation and storage. Further, the vaccine may be prepared in the form of a mixed vaccine which contains the glycosylated pili described above and at least one other antigen as long as the added antigen does not interfere with the effectiveness of the vaccine and the side effects and adverse reactions are not increased additively or synergistically.
The vaccine may be stored in a sealed vial, ampule or the like. The present vaccine can generally be administered in the form of a liquid or suspension. In the case where the vaccine is in a dried form, the vaccine is dissolved or suspended in sterilized distilled water before administration. Generally, the vaccine may be administered orally, subcutaneously, intradermally or intramuscularly but preferably intranasally in a dose effective for the production of neutralizing antibody and protection from infection or disease.
In another embodiment, the present invention relates to a method of reducing Gram-negative bacterial infection symptoms in a patient by
administering to said patient an effective amount of anti-pili or anti-glycosylated pili antibodies, or pili (glycosylated or unglycosylated) as described above, or other agents capable of blocking pili function. Since glycosylated pili are involved in adhesion of bacteria to host cells, inhibiting or reversing the adhesion of bacteria may reduce or eliminate the development of Gram-negative bacterial infections. When providing a patient with anti-pili or anti-glycosylated pili antibodies, or agents capable of inhibiting pili function or expression for example receptor analogs such as pili themselves to a recipient patient, the dosage of administered agent will vary depending upon such factors as the patient's age, weight, height, sex, general medical condition, previous medical history, etc. In general, it is desirable to provide the recipient with a dosage of the above compounds which is in the range of from about lpg/kg to 10 mg/kg (body weight of patient), although a lower or higher dosage may be administered. In another embodiment, the present invention provides a method for large scale production of pili. Pure, undenatured pili in milligram quantities are required for vaccine use. Current methods of pili purification present difficulties. Cells grown on solid media adhere tenaciously, producing large quantities of slime. The vigorous treatment required to dislodge the cells damages the pilus fibers and releases cellular materials (LPS is a common contaminate; flagella, which copurify with the pili are usually present). Growth in broth cultures, especially using high levels of agitation, suppresses production of pili, probably because they are broken off during this vigorous agitation. The present method overcomes the suppression of pili production in broth cultures by using RpoN" strains for pili production. Any Gram-negative bacterial strain can be made RpoN according the published protocols (Ishimoto and Lory, 1989, Proc. Natl. Acad. Sci. USA 86: 1954-1957). This new method routinely yields milligram quantities of pure native pili per liter of culture by overcoming the suppression of pili production in broth and comprises the steps of:
(i) transforming an RpoN" Gram-negative bacteria with a vector containing the pilin structural gene with or without pilO;
(ii) growing the transformed bacteria in broth culture with vigorous agitation; and
(iii) purifying pili from the supernatant fluid of said broth cultures.
In yet another embodiment, the present invention provides immunogenic epitopes from the pilA structural pilin gene representing possible glycosylation recognition sequences. These epitopes were mapped by standard peptide mapping techniques. These epitopes include the amino acid sequences designated SEQ LD NO:3 and SEQ LD NO:4. These peptides can be generated in any manner, including for example, chemical synthesis, or expression of a recombinant expression system. In addition the polypeptide can be fused to other proteins or polypeptides which increase its antigenicity, such as adjuvants for example, thereby producing higher liters of anti-pilin antibodies for protection against P.aeruginosa infection. In addition, these peptides may be used with or without glycosylation as a vaccine or for the production of antibodies which can then be used to generate passive immunity against P. aeruginosa infection.
In addition, the strain 1244 peptide sequence conferring glycosylation can be incoφorated into other P. aeruginosa cell surface proteins of potential vaccine value using standard recombinant DNA methodologies. Examples of such cell surface proteins include flagella and outer membrane proteins such as F and P. This recognition sequence could be likewise incoφorated into surface proteins of vaccine potential from other bacteria such as Bordetella pertussis, Francisella species, Neisseria meningiditis, Neisseria gonorrhoeae, Vibrio cholerae, Brucella species, certain strains of Escherichia coli, and Yersinia species. Expression of pilO from a plasmid in such an organism would result in the addition of the organisms specific O-antigen to this protein.
Described below are examples of the present invention which are provided only for illustrative puφoses, and not to limit the scope of the present invention. In light of the present disclosure, numerous embodiments within the scope of the claims will be apparent to those of ordinary skill in the art.
The following MATERIALS AND METHODS were used in the examples that follow.
Bacterial strains and culture conditions. P. aeruginosa 1244, a clinical isolate which has been used in pilus-mediated adhesion studies (Ramphal et al, 1984, Infect. Immun. 44: 38-40), was provided by A.T.
McManus, U.S. Army Institute of Surgical Research, San Antonio, Texas. P. aeruginosa strain I244N3, a mutant which is unable to make pili or produce pilin (Ramphal et. al, 1991, Infect. Immun. 59: 1307-131 1) due to an inactivated rpoN gene, was furnished by S. Lory, University of Washington. Cultures were grown on LB medium (Sambrook et al., 1989, Molecular Cloning: a Laboratory Manual, vol. 1, 2nd edn. Cold Spring Harbor, N.Y.:
Cold Spring Harbor Laboratory) at 37°C. Antibiotic concentrations in selective media used for P. aeruginosa were as follows: carbenicillin (Cb), 500 μg ml-'; tetracycline (Tc), 50 μg ml"1. Antibiotics used with E. coli were: ampicillin (Ap), 75 μg ml"1; spectinomycin (Sp), 25μg ml"1; tetracycline (Tc), 10 μg ml"'. Nucleotide sequencing. The Sanger dideoxy method (Sanger et al, 1977, Proc. Natl. Acad. Sci. USA 74: 5463-5467) was used. The template was single-stranded M 13 subclones of phage Lambda or plasmid clones (Castric et al., 1989, Mol. & Gen. Genet. 216: 75-80) containing DNA downstream from the pilA gene. Synthetic primers, derived from known sequences, or universal primers were employed.
Plasmid constructs. The plasmid pPAC46, which contained both pilA and pilO, was constructed by ligating the Sphl-HindUI plasmid fragment containing the pilA and adjacent DNA (Fig. 2) of pPAC202 (Castric et al., 1989, supra) to plasmid pUC 18 digested with these same enzymes. The EcoRI-H ndiπ fragment of this construct, pPAC124, was ligated with the broad host range expression vector pMMB66EΗ (Apr, lacP; Furste et al, 1986, supra) which had been digested with the same restriction enzymes. Plasmid pPAC24, which contained pilA, but not pilO, was constructed by ligating the pPAC 124 EcoK -Nhel fragment containing the pilA gene with pUC 19 digested with EcoRI and Xbal. The EcoRI-H dlll fragment of this construct, which contained only the pilA gene, was ligated with pMMB66EΗ digested with the same restriction enzymes. The pilA gene of both pPAC24 and pPAC46 was under control of the vector tac promoter. Since the Sphl site used in plasmid construction is located within the pilA promoter neither pPAC24 nor pPAC46 were able to express the pilin structural gene using the P. aeruginosa promoter. Plasmid DNA was introduced into E. coli by transformation (Sambrook et al., 1989, supra), and was transferred to P. aeruginosa by triparental mating (Ruvkun & Ausubel, 1981, Nature 289: 65-88).
Northern blot analysis. RNA was extracted as described by Reddy ( 1989, In Current Protocols in Molecular Biology, vol. 1 , 4.4.1.-4.4.7. Edited by F. M. Ausubel et al. New York: John Wiley) and separated by formaldehyde-agarose gel electrophoresis, stained with ethidium bromide, and transferred to nitrocellulose paper by capillary blot as described by Sambrook et al., (1989, supra). Probe DNA, isolated from pPAC24 or pPAC46, was labelled by nick translation using [α-12P] dCTP. Prehybridization, hybridization, and washing steps were as described by Sambrook et al., 1989. Detection of hybridization was by autoradiography. Densitometric scanning was carried out using an LKB Ultroscan laser densitometer.
Purification of pili. Production of pili by expression of the pilA genes of plasmids pPAC24 and pPAC46 in P. aeruginosa 1244N3 was carried out using LB agar- or LB broth- cultures grown in the presence of 5 mM isopropyl-thiogalactoside (IPTG). LB agar-grown cells were resuspended in LB broth. These cells (as well as broth-grown cells) were depiliated by four excursions through a 22-gauge needle. Cells were removed by centrifugation (7,500 g for 15 min). The pili remaining in the supernatant fluid were purified by a variation of the method of Silipigni-Fusco (1987, Studies in the role of somatic pili as virulence and immunity factors in the pathogenicity of Pseudomonas aeruginosa. Ph.D. thesis, University of Pittsburgh, USA). In this procedure the supernatant fluid was made 0.1 M with respect to MgCl2, and stored on ice for 60 min. The resulting precipitate, which contained the pilus fibres, was removed by centrifugation at 12,000 g f or 15 min.
Pilin analysis. N-terminal amino acid sequence analysis and amino acid analysis was performed on purified pilin from strain 1244N3(pPAC24). This protein was subjected to PAGE (15%T) which was followed by electroblotting to polyvinylidene difluoride paper. Preliminary staining showed that pilin was the major protein present and that it was well separated from the minor contaminants present. Pilin bands were excised and subjected to gas- phase sequencing and to amino acid analysis (University of Pittsburgh Peptide Facility).
Pilin immunoblot analysis. Pilins were separated by PAGE ( 12.5%T in the presence of either 0.1 % SDS at 5°C or 30.0 mM octyl glucoside at 15°C) or subjected to isoelectric focusing (pH 3.0 to 9.5) in the presence of 30.0 mM octyl glucoside at 15°C using the LKB-Pharmacia Phastsystem.
Proteins were transferred to nitrocellulose paper by diffusion blotting; pilin adsorbed to the paper was detected using anti-pilin monoclonal antibody 6-45 (Saiman et al., 1989, Immun. 57: 2764-2770) as previously described (Castric et al., 1989, supra). The presence of pilin-bound sugar residues was detected by first derivatizing purified pili using the DIG Glycan Detection kit of
Boehringer Mannheim Biochemica (Indianapolis). This protein was subjected to SDS-PAGE (12.5%T) using the BioRad MiniProtean II system in which temperature was neither controlled nor monitored. Pilin was electroblotted to nitrocellulose paper, probed with an alkaline phosphatase- labelled antibody specific for the hapten used in pilin derivatization, and developed as described by Boehringer Mannheim Biochemica (Indianapolis).
Electron microscopy. Cells to be analyzed by electron microscopy were grown on LB agar plates at 37°C for approximately eighteen hours and suspended in phosphate buffered saline. The cells were coated on 200 mesh formvar-coated copper grids, subjected to staining with 1 % uranyl acetate, and viewed in a Philips 201 electron microscope.
Pili functionality tests. The phage sensitivity test was performed by streaking a loop of pilus- specific phage PE69 on an LB agar plate. This was cross-streaked with diluted P. aeruginosa 1244 strains to be tested. Phage sensitivity was inteφreted from the absence of growth at the cross-streak junction. Twitching (Henrichsen, 1983, Annu. Rev. Microbiol. 37: 81-93) was determined by streaking strains of interest on a well dried LB agar plate where motility was scored as spreading growth at between 48 and 72 hours at 37°C. EXAMPLE 1
Nucleotide sequence analysis
The nucleotide sequence downstream from the P. aeruginosa strain 1244 pilA gene contains a potential transcriptional termination structure situated between positions 626 to 708 (noted previously in Castric et al., 1989, supra). A ribosome-binding site (GGAG) is seen at position 717 followed closely by three start codons, the first of which is located immediately in frame with a stop codon (TGA). The second and third, GTG and ATG, are in frame with each other and begin an open reading frame (referred to hereafter as pilO) which extends 1383 base pairs, using the ATG codon, to position 21 14. Codon usage of the 461 codons of the pilO gene is consistent with that of most other P.
aeruginosa genes (West & Iglewski, 1988, Nucleic Acids Res. 16: 9323-9335). However, significant differences are seen when it is compared with the adjacent pilA gene or with the pilA genes of other P. aeruginosa strains (West & Iglewski, 1988, supra; Castric & Deal, 1994, supra). While the phe codons, TTT and TTC, have frequencies of 20/29 and 9/29, respectively, in the pilA gene, these codons occur at rates of 6/25 and 19/25, respectively, in the pilO gene. The arg codons, CGT and GCG, appear at rates of 26/31 and 2/31 in the pilA gene, but occur at rates of 7/31 and 1 1/31, respectively, in the pilO gene. In addition, the G+C% content of pilO (60.1%) is consistent with the general range given for P. aeruginosa chromosomal DNA (West & Iglewski, 1988), but quite different from the value of 52.2% determined for the strain 1244 pilA gene. A search of the Genbank database revealed no sequences with significant homology to the pilO gene.
A tRNAu,r gene, which contains an anticodon recognizing the rare codon ACG, can be seen just downstream of the pilO gene between positions 2166 and 2241, and is followed, between positions 2245 and 2282, by a potentially bidirectional transcriptional stop containing a 17 bp loop stem. A tRNA gene and transcriptional stop region have been noted previously (Hobbs et al, 1988, Gene 62: 219-227) as occurring immediately downstream from the P. aeruginosa strain PAK pilA gene, and may also be seen in the analogous region of the pilA genes of P. aeruginosa strains PAO and PA 103 (Johnson et al., 1986, supra). A homology comparison (Fig. 1) shows that the tRNA- transcriptional stop region described in this paper is virtually identical with the i'-A-proximal regions of strain PA 103 beginning at position 2421 and continuing 275 base pairs to the end of the sequence. It is interesting to note that the first 5 bases of this region (GAGTG) are also found, as a direct repeat, in the pilA-0 intragenic region gene beginning at position 676, suggesting a possible site of genetic recombination. These results are summarized in Fig. 2 where the organization of these regions may be compared. EXAMPLE 2
Transcription of pilO
Northern blots (Fig. 3) of strain 1244 mRNA showed that probe 1, composed of pilA DNA, recognized 650 base (RNA 2) and 2200 base (RNA 1) species. The smaller transcript was present in approximately a 100-fold excess over the larger mRNA as determined by densitometric scanning. By analogy
with work on other P. aeruginosa pilA genes (Johnson et al., 1986) the transcription startpoint may be presumed to begin between positions 150 and 160, suggesting that the larger transcript extends into the pilO region. The intermediate-sized RNA fragments might be formed by early termination, due to the loop structure referred to earlier, or might be degradation products of the larger species. Probe 2, which was composed of pilO DNA, hybridized only with the larger fragment and the intermediate pieces suggesting that the origin of the 2200 base mRNA is in the pilA region and that synthesis of this molecule extends downstream through the pilO gene. This was confirmed by the reaction of probe 3 which was composed of DNA from the latter part of the pilO gene and the tRNA-transcriptional stop region. This probe hybridized with the larger fragment but with neither the pilA transcript nor the intermediate fragments. This probe also hybridized with a very small RNA population, presumably tRNA produced by the p /0-associated gene as well as with cross-reacting species. Overall these results indicate that pilA, pilO and probably the adjacent tRNA gene are part of a single transcriptional unit which utilizes the pilA promoter.
EXAMPLE 3 Influence of pilO on pilus function Since both pilA and pilO are part of the same transcriptional unit, the inactivation of the pilA promoter will also eliminate pilO expression. P. aeruginosa strain 1244N3 is a mutant which is unable to make pili or produce pilin (Ramphal et al., 1991, Infect. Immun. 59: 1307-131 1 ) due to an inactivated rpoN gene. This strain was used as the genetic background for expression of the pilA gene, carried on recombinant plasmids pPAC24
(containing only pilA) or pPAC46 (bearing both pilA and pilO), under control of a tac promoter. Electron microscopy showed that while strain 1244N3 produced no pili both derivatives 1244N3(pPAC24) and 1244N3(pPAC46), when grown in the presence of IPTG, produced pilus fibres which were indistinguishable from those of the wild-type (results not shown). Both strains 1244N3(pPAC24) and 1244N3(pPAC46), in the presence of IPTG, were sensitive to the pilus-specific bacteriophage PE69 and demonstrated twitching motility on dried agar plates, properties lacking in strain 1244N3. These results indicated that the absence of pilO did not appear to influence the ability of the
pilus to extend and retract, qualities necessary for twitching and for phage sensitivity.
EXAMPLE 4 Influence of pilO on pilin structure Although strain 1244N3 was unable to produce pilin, as determined by
Western blot (results not shown), complementation of this strain with either plasmid pPAC24 or pPAC46, under inducing conditions, allowed production of this protein (Fig. 4A). While the molecular weight of mature pilin of strain 1244 predicted from the nucleotide sequence of the pilA gene (Castric et al, 1989, supra) is 15,653, the apparent size of pilin produced by strain 1244N3(pPAC46), or by wild-type strain 1244 (results not shown) is approximately 16,900. Pilin produced by strain 1244N3(pPAC24). which lacks a functional pilO gene, had an apparent molecular weight of 15,600. Identical results were obtained when gradient SDS-PAGE was employed. A small fraction of the pilin produced by strain 1244N3(pPAC24) migrated with wild-type pilin when the BioRad MiniProtean II PAGE system (15% T) was employed (results not shown).
To explore the significance of this apparent molecular weight difference it was necessary to see if the N-terminus of pilin produced by strain 1244N3(pPAC24) was in any way altered. When this protein was subjected to N-terminal amino acid analysis, the sequence of mature pilin, XTLLELM (the first residue produced no reaction presumably because it was the masked amino acid N-methyl-phenylalanine), was obtained. Amino acid analysis of blotted pilin was also carried out to determine the integrity of the carboxy-terminal region. The pilin of P. aeruginosa 1244 contains 6 prolines (Castric et al.,
1989), mainly in the carboxy-terminal region. The observed molecular weight difference of approximately 1,200, if caused by cleavage in this region, would require breaking the bond between residues 136 and 137 of mature pilin resulting in a change in apparent proline number from 6 to 3. Normalization (with alanine) of actual values obtained gave a proline/alanine (P/A) ratio of 0.36, with a P/A ratio of 0.20 predicted for a truncated form and a P/A ratio of 0.35 predicted for mature pilin. Normalization with leucine values gave a proline/leucine (P/L) of 0.68 (a P/L ratio of 0.33 is predicted for a truncated form and a P/L ratio of 0.67 for mature pilin). These results suggest that the pilin carboxy-terminal region must be substantially intact.
Purified pili from strains 1244N3(pPAC24) and 1244N3(pPAC46) were treated with periodic acid to oxidize any sugar residues present. These proteins were then treated with digoxygenin- succinyl-ε-amidocaproic acid hydrazide which will form a covaleπt bond with oxidized sugars. After SDS-PAGE these proteins were electroblotted to nitrocellulose paper and probed with an anti- digoxygenin antibody preparation. Fig. 4 shows that pilin from strain 1244N3(pPAC46) reacted with this antibody indicating the presence of sugar moieties, while pilin from strain 1244N3(pPAC24) gave no reaction.
Pili were dissociated into pilin monomers and dimers in the presence of 30.0 mM octyl glucoside (Watts et al, 1982a, Can. J. Biochem. 60: 867-872; Watts et al, 1982b, /. Bacteriol. 151: 1508-1513; Watts et al, 1983, Biochemistry 22: 687-691), subjected to isoelectric focusing, then blotted to nitrocellulose paper, and probed with pilin-specific monoclonal antibodies. Pilin produced by strain 1244N3(pPAC46) or by wild-type strain 1244 (results not shown) had a pi of 4.75 (Fig. 4B). Pilin from strain 1244N3(pPAC24), which lacked a functional pilO gene, had a pi of approximately 6.25. The pi of mature strain 1244 pilin is predicted from the pilA gene sequence (assuming that the amino-terminus is blocked and the two cysteines form a disulfide) to be 7.00. These results indicate that a significant alteration in pilin charge arrangement (neutralization of positive charges or introduction of negative ones) is brought about by the presence of the pilO gene. The difference in charge between these two pilin forms was confirmed by PAGE in the presence of 30.0 mM octyl glucoside at pH 8.8. Pilin from strain 1244 or strain 1244N3(pPAC46) had a greater net negative charge than pilin from strain 1244N3(pPAC24) (results not shown). Pilin from strains 1244 and
I244N3(pPAC46) also focused at pH 4.75 in the presence of 8.0 M urea and 2.5% (v/v) Triton X-100 (results not shown). Pilin preparations from strain 1244N3(pPAC46) or the wild-type strain contained trace amounts of the neutral pilin form (results not shown) possibly due to chemical or enzymatic action. The small amounts of the acidic pilin form produced by strain
1244N3(pPAC24) (Fig. 4B), as well as the higher molecular weight form described above, may be due to low levels of pilO gene expression by the host strain. These results altogether suggest that the P. aeruginosa strain 1244 pilO
gene is required for a posttranslational pilin modification, specifically a glycosylation.
EXAMPLE 5 Preparation of glycosylated PA 1244 pili One liter (in a 2.8 liter Fernbach flask) of a medium (LB broth containing
Carbenicillin [200 μg/ml], Tetracyline [50 μg/ml], and isopropyl thiogalactoside [IPTG, 5 mM]) was inoculated with 25 ml of an overnight culture of Pseudomonas aeruginosa 1244N3(pPAC46) grown with the same medium (minus the IPTG). This host strain is RpoN". The inoculated medium was incubated at 37C with rotary agitation 250 φm for 7 hours. The overnight starter culture was grown under the same conditions in a 125 ml Erlenmyer flask.
After incubation the cells were removed by centrifugation (4.200 xg for 15 min). 30 g of Polyethylene glycol (PEG) 6000 and 20.3 g MgCl2 were added to the supernatant fluid which was stored overnight at 4C. The light grey-tan precipitate (containing the pili) was removed by centrifugation (13,20 xg for 30 min).
This material was suspended with 50 ml 10.0 mM Tris/HCl, pH 7.6 containing 20% sucrose and centrifuged (4,200 xg for 15 min). The precipitate was discarded and the supernatant fluid was reprecipitated with PEG and MgCl2 as described above, and stored overnight at 4C. The light grey-tan precipitate (containing the pili) was removed by centrifugation (13,200 x g for 30 min) and suspended with 25 ml 10.0 mM Tris/HCl, pH 7.6 containing 20% sucrose.
Ammonium sulfate was added to 35% saturation. After 30 min at 4C this material was centrifuged (4,200 xg for 15 min) and the precipitate discarded. Ammonium sulfate was added to the supernatant fluid to 65% saturation. After 60 min at 4C this material was centrifuged (4,200 xg for 15 min) and the supernatant fluid was discarded. The pellet contained the pili were subjected to poiyacrylamide gel electrophoresis (PAGE) which showed, with silver staining, only trace amounts of contaminating protein and only minor amounts of LPS on gels in which pilin was overloaded. This procedure routinely produced 10 to 20 mg of pilin protein (as determined by the BCA test) per liter of cells.
EXAMPLE 6 Animal model
ICR mice (25-30 g) were immunized with P. aeruginosa strain 1244 pili at a concentration of 5 mg/mouse/dose diluted in physiologic saline. The following immunization schedules were used to determine antibody response:
i.n./i.n., s.c./s.c, i.p. .p., i.n./s.c, s.cJi.n., i.n./i.p., i.p./i.n.. The time interval between the doses was 7 days. For i.n. immunization, mice were anesthetized i.p. with ketamine HCl (80 mg/kg) and xylazine HCl (8 mg/kg) prior to the instillation of pili. Pili were delivered i.n. in a final volume of 25 μl using sterile aerosol resistant pipet tips for each mouse to prevent contamination. The final volume for i.p. and s.c. injection was 100 μl. Control mice received physiologic saline only
At days +3, +7, +10 and +14 after the second dose, mice were sacrificed by CO2 inhalation to obtain serum samples via cardiac puncture as well as bronchoalveolar lavage (BAL) samples for antibody titers. For BAL samples, lungs were washed once with 1 ml of sterile physiologic saline via a 25 G hypodermic needle inserted into the trachea.
Antibody titers were determined by means of an ELISA using 96-well plates coated with P. aeruginosa 1244 pili at a concentration of 2 mg/ml (50 ml well, 4°C, over night [O/N]). After blocking and washing, samples were serially diluted (2-fold) in duplicate in blocking buffer and incubated O/N at 4°C.
Bound antibodies were detected using goat-anti-mouse-IgG/alkaline phosphatase labelled, goat-anti-mouse-IgM/alkaline phosphatase labelled, and goat-anti-mouse-IgA/alkaline phosphatase labelled (Incubation O/N, 4 C); plates were developed with p-Nitrophenylphosphate in diethanolamine buffer and read in a Biotek® Ceres 900 C ELISA reader. ELISA titers are defined as log10 of the dilution which gave a change of A^ of 0.200 after 30 min.
For protection studies, P. aeruginosa 1244 was grown to mid-log phase in trypticase soy broth for 4 h at 37°C. After washing the bacteria with physiologic saline, the OD650 was adjusted to 0.480 which corresponded to an estimated CFU count of 2 x lOVml. Mice were challenged i.n. using 2 different doses (LDI00, LD5) at day +7 after the second dose of pili. Anesthesia was done as described above, and bacteria were delivered in a final volume of 50 ml. Mortality and body weight were monitored daily for 14 days. Control mice received physiologic saline only. Time to recovery in sublethal challenge experiments was defined as number of days until the baseline body weight was regained or (if animals did not reach their baseline body weight) as number of
days until stabilization of body weight (3 consecutive days with weight change
0.5 g).
TABLE 1 . ANTIBODIES AGAINST PILI Mice: ICR)
Route,
Ig class BAL Serum
: Sample
I day: 3 7 10 14 10 14
IN/IN
IgG 2.76 2.80 2.15 1.83 4.13 5.59 4.09 5.12
IgM 1.85 0.50 0.50 0.50 3.91 2.97 2.93 2.80
IgA 1.90 2.74 2.00 0.50 2.50 2.40 2.09 0.50
IN/SC
IgG 0.50 1.85 1.77 1.70 3.64 5.61 5.78 5.61
IgM 0.50 0.50 0.50 0.50 3.44 3.95 3.64 2.85
IgA 0.50 0.50 0.50 0.50 1.15 1.40 1.27 0.50
TABLE 2. ANTIBODIES AGAINST LPS (Mice: ICR)
Route,
Ig class BAL Serum Sampl e day: 3 7 10 14 10 14
IN/IN
IgG 0.50 0.50 0.50 0.50 2.05 1.90 1.77 2.37
IgM 0.50 0.50 0.50 0.50 2.68 2.43 1.96 1.97
IgA 0.50 0.96 0.50 0.50 0.50 0.50 0.50 0.50
IN/SC
IgG 0.50 0.50 0.50 0.50 2.22 2.43 2.13 2.09
IgM 0.50 0.50 0.50 0.50 2.79 2.90 2.83 2.69
IgA 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50
TABJ E3, ANTIBODIES AGAINST PILI CMice: C3H/I
Route BAL Serum
Ig class IgG IgM IgA IgG IgM IgA
IN/IN 0.50 0.50 0.50 3.26 3. 1 1 0.50
IN/SC 0.50 0.50 0.50 3.33 3.35 0.50
Route BAL Serum
Ig class IgG IgM IgA IgG IgM IgA
IN/IN 0.50 0.50 0.50 1.49 2.09 0.50
IN/SC 0.50 0.50 0.50 1.39 1.86 0.50
notes:
All data are medians (not means) from 3 mice. They represent the logl0 of 10-fold dilutions which gave a change of A4I0 of 0.200/15 min.
Background readings (everything except serum or BAL samples) were always below 0.020. Serum samples from normal ICR as well as C3H/HeJ mice gave no readings higher than the background. Data from C3H/HeJ mice are from day +7 after the 2nd dose only. Limit of detection: 0.499 1:3
TAB LE 5.
Group # Treat¬ Challenge with Survival (L/D) Survival @ ment end of study
Strain CFU given ay
0 1 2 3 4 5- 13 14 alive/ % total alive
10-6 i.n. -i.n. P.aer. 6.1 x IO6 5/0 5/0 5/0 3/2 3/0 3/0 3/0 3/5 60
1-17 12.4.4 2.25 x 10" 5/0 4/1 4/0 4/0 4/0 4/0 4/0 4/5 80
1-20 «• " 6.75.x 10" 5/0 5/0 4/1 4/0 3/1 3/0 3/0 3/5 60 total " " 5.03 x IO6 15/0 14/1 13/1 1 1/2 10/1 10/0 10/0 10/15 66.70
10-6 i.n.-s.q. 6.1 x 10ή 5/0 4/1 1/3 1/0 1/0 1/0 1/0 1/5 20
1-17 - 2.25 x IO6 5/0 5/0 4/1 4/0 4/0 4/0 4/0 4/5 80
1-20 •' 6.75.x 10A 5/0 4/1 1/3 1/0 1/0 1/0 1/0 1/5 20 total " 5.03 x IO6 15/0 13/2 6/7 6/0 6/0 6/0 6/0 6/15 40
10-6 controls •• 6.1 x 10" 4/0 1/3 0/1 0/40 0
1- 17 •• » 2.25 x IO6 4/0 3/1 2/1 0/2 0/4 0
1-20 " " 6.75.x 10* 5/0 3/2 1/2 0/1 0/5 0 total " " 5.03 x IO6 13/0 7/6 3/4 0/3 0/0
aCFU given in "total" represents the mean out of the CFU of the 3 experiments (SEM = 1.99 x IO6)
Every immunization schedule tested resulted in IgG and IgM antibody titers in serum as well as in BAL fluid. Only immunization twice via the i.n. route, however, yielded significant levels of IgA antibodies both locally and systemically. Based on these findings, we chose to compare wot different routes (i.n./i.n., i.n./s.q.) with the bacterial challenge given at day +7 after the boost dose. While all of the control mice died within 3 days, 66.7% of the mice immunized i.n./s.c. (P=0.031). In sublethal infections, time to recovery as measured by regaining body weight was shorter in the group immunized i.n./i.n. (7. l± 0.8 days, mean ± SEM) than in the control group (9.6 ± 0.8 days). Thus, we were able to demonstrate that pili from P. aeruginosa are highly immunogenic. Mucosal immunization via the intranasal route protects mice significantly from a lethal pulmonary challenge with the homologous strain and leads to faster recovery in sublethal lung infections. EXAMPLE 7
Location of the site of pilin glycosylation Digestion of pure glycosylated strain 1244 pilin (apparent molecular weight as determined by SDS-PAGE was 16,800) with V8 protease produced a 9,000 molecular weight peptide which reacted with anti-LPS monoclonal 1 1.14 on Western blot. N-terminal analysis of this fragment showed that this peptide with this N-terminus would be predicted to have a molecular weight of 7,700. Altogether, these results show that the pilin glycosylation site is in the region bounded by residue 75 and the carboxy-terminus, encompassing peptide regions 3 (SEQ ID NO: 3) and 4 (SEQ LD NO:4), two regions found to contain linear B-. cell epitopes (Castric and Deal, 1994, supra) and may be important in peptide vaccine design. Further, peptide sequencing indicated that residue 95 did not produce the expected threonine residue suggesting that epitope region 3 is the site of glycosylation.
EXAMPLE 8 Isolation and characterization of pilin glycan.
Pure pili were treated with a combination of Proteinase K and Pronase
(48 hrs at 45°- 55'C in the presence of toluene). This digest was subjected to gel filtration (Sephadex G-25 superfine grade) producing the results seen on Fig 6. The isolated glycan was analyzed using several methods. D Size determination :
Gel filtration (Sephadex G-25 superfine grade) of the isolated glycan using a calibrated column (lactose and glucose as size standards) showed at least two peaks in the molecular weight range of 400 to 650. Mass spectrometry (FAB) of the isolated glycan gave two peaks (masses 460 and 613). 2) Chemical composition: a) Sugars: Thin layer chromatography of trifluoroacetic acid hydrolyzed pili clearly showed the presence of at least two sugars. Mass spectrometry of trifluoroacetic acid hydrolyzed glycan gave peaks at masses 155 and 307, values compatible with known sugars of the P. aeruginosa 1244 LPS O-antigen repeating unit. b) Amino acids: Amino acid analysis of trifluoroacetic acid hydrolyzed glycan showed that serine was the dominant residue. Mass spectrometry of trifluoroacetic acid hydrolyzed glycan gave a peak at mass 107 which was similar to the expected value for serine.
The antigenicity of the pilin glycan was studied. The isolated glycan competes with pure pili (Fig 7) for reaction with monoclonal 1 1.14 (an antibody which reacts with both strain 1244 LPS and pili). These results show that pilin glycans are relatively small (probably mono and di-saccharides). Small size indicates that (since glycosylation appears to change the pilin molecular weight by a value of 1200) several copies of these glycans exist on the pilus surface. In addition, a certain amount of heterogeneity among the glycans is likely and the pilin glycan contains an epitope which is also found on the strain 1244
LPS O-antigen.
These results suggest that this epitope can be chemically attached to another carrier (such as cholera toxin) thereby transferring immunogenicity and antigenicity to other carriers, thereby broadening vaccine applicability.
EXAMPLE 9 Heterologous glycosylation
The plasmids described above (which contain either the pilA gene alone (pPAC24) or both the pilA and pilO genes (pPAC46) can easily be moved (by conjugal mating) into various P. aeruginosa strains where these pilin genes can be expressed through IPTG stimulation of the tac promoter. In the absence of pilO, the 1244 pilin produced had the apparent molecular weight predicted by the gene structure. In the presence of the gene, the 1244 pilin produced appeared to be modified as indicated by apparent molecular weight. If these modified pilins contain glycan composed of host cell LPS O-antigen building blocks it is potentially possible to detect this material using O-antigen type- specific antisera. Experiments exploring this possibility are as follows.
LPS serotype [Liu et al., 1983 Int. J. Syst. Bacteriol. 33: 256-264] and the ability of pertinent strains to produce pili are given in Table 6. The reactions (Western blot) of monoclonal antibodies used is given in Table 7. Table 6: Pseudomonas aerueinosa strains used:
1244 1244N3a) PAKN1"
LPS type: 07 07 06
Pili: +++ A)Pilin-negative mutant.
Table 7: Reaction of monoclonal antibodies employed: Pili LPS
1244 07"' 06b) M
5.44 ++++
1 1.14 ++++ ++++
1.2.48 - - ++++
2.34.3 - - ++++ 7.72.1 - - ++++
6.8.1 128.1
2.4.1 - - ++++
106.1
a) LPS prepared from strain 1244. b) LPS prepared from strain PAKN 1.
Pilin produced from plate cultures (grown in the presence of IPTG) was subjected to isoelectric focusing, followed by diffusion blotting to PVDF paper. These blots were then probed with monoclonal antibodies giving the results seen in Table 8 (numbers in parentheses are approximate pi's).
rnopQcJpnal antibodie ,
1244N3 1244N3 PAKN1 PAKN1
(PPAC34) (PPAC46) (PPAC24) (pPAC46
Mabs
5.44 ++++(6.8) ++++(4.7) ++++(6.8) ++++(4.7)
1 1.14 - ++++(4.7) - -
1.2.48 ND ND - ++++(4.7)
2.34.3 ND ND - ++++(4.7)
7.72.1 ND ND - ++++(4.7)
6.8.1 ND ND - ++++(4.7)
128.1 ND ND - ++++(4.7)
2.4. 1 ND ND - -
106.1 ND ND - -
The results seen may be summarized as follows: 1. Testing with monoclonal 5.44 (specific for 1244 pilin protein) shows that 1244 pilin protein was produced in either of the pili-negative strains 1244N3 (LPS type 07) or strain PAKN1 (LPS type 06), using either pPAC24 or pPAC46.
2. Testing with monoclonal 1 1.14 (which reacts with either pure pilin or pure LPS, see Table 7) shows that pilin-associated 07 LPS antigen was seen only when a functional pilO gene was present (pPAC46), and only in a 07 LPS producing strain.
3. Testing with anti-06 LPS (which do not react with pure 1244 pilin, see Table 7) showed that pilin associated 06 LPS antigen was seen in 5 out of 7 cases, but only when a functional pilO gene (pPAC46) was present.
Similar results were seen when strain 653A (International type 06) was substituted for strain PAKNl.
Altogether these results lead to two important conclusions. First, the LPS 06 epitope is transferred to 1244 pilin when this protein is produced (in the presence of pilO) in strain PAKNl, therefore, PilO is non-specific in the type of O-antigen components attached to 1244 pilin even though the O-antigen repeating are structurally distinct. Second, the possibility of LPS contamination of these samples blotted from SDS-PAGE gels is eliminated for two reasons. Pilin would not focus at pH 4.7 if there was even one LPS molecule per pilin monomer. Two of the anti-06 LPS monoclonals (which strongly react with extracted PAKNl LPS as determined by Western blot) do not react with. LPS antigen associated with blotted pilin produced in the presence of pilO in strain PAKNl. These nonreactive monoclonals must recognize LPS components which are not present as part of the pilin glycan. Furthermore, these results suggest that O-antigen components of any serotype can be attached to the 1244 pilus. This introduces the possibility of producing vaccine cocktails which contain pili glycosylated with components of all the major LPS O-antigens. These results further bring to surface the possibility of expressing these pilin genes in other Gram-negative bacteria thereby attaching LPS O-antigen components to the strain 1244 pilus. This would extend the range of the vaccine to a variety of diseases. In this situation, the pilus would serve as a new type of carrier, taking advantage of its natural adjuvant properties.
EXAMPLE 10 Surface Peptide Epitopes of P. aeruginosa 1244 Pilus
Vaccine design requires knowledge of epitope structure. While B- and T-cell epitopes of P. aeruginosa PAO and PAK pili have been determined in general terms (Watt, et al, 1983, Infect. Immun. 42: 1 13-121 ; Sastry et al, 1985, Can. J. Biochem. Cell. Biol. 63: 284-291), nothing is known of the common pilus type produced by strain 1244. Analysis of this pilus was carried out using the Geysen test (Carter, 1994, In: Methods in Molecular Biology. Vol 36: Peptide Analysis Protocols (BM Dunn and MW Pennington, eds.), pp 207- 223, Humana Press, Towtowa, NJ; Deal, 1994, In: Current Protocols in Immunology (J. Collegan, ed.) Supplement 10, Unit 9.7.1-14, John Wiley and Sons, New York; Geysen et al, 1984, Proc. Natl Acad. Sci. USA 81:3998-
4002) in which tethered peptides (12-mers, 1 residue overlap per peptide) representing the entire pilin primary structure were probed with mouse anti- native 1244 pilus polyclonal sera. Results obtained testing five sera produced results which are summarized by the epitope map of Figure 9. Regions 1 and 4 were determined to be immunodominant based on frequency and intensity of reaction. Since the anti-pilus sera were raised against native pi these epitope regions represent portions of the pilin primary structure which occupy the pilus fiber surface, and so are key targets m peptide vaccine design.
In order for a peptide to provide a protective response it must occupy a part of the pilus surface which is involved in the two activities of the pilus cπtical to pathogenesis: a)adhesion tothe host cell, and b) retraction of the pilus fiber (which insures locking on of the pathogen to the host cell surface) Since both activities are required for colonization and, interference of either by the immune response would be protective. Since region 1 (SEQ LD NO: 5) is a potential protective epitope, it is important to note that it contains a sequence (LKT--E) common to most P. aeruginosa pilins (Castπc and Deal, 1994, supra). Anti- 1244 pilus monoclonal 5.44 also maps to this region (Castric and Deal, 1994, supra). This monoclonal reacts (Western blot) with pilins from strains which only contain this sequence similarity indicating that these residues form the core of this epitope region. The carboxy-proximal portion, roughly analogous to region 4 of 1244 pilin, of the strain PAO and PAK pilins house the host receptor binding site (Lee et al. , 1989, Molec. Microbiol 3: 1493-1499; Doig et al. ,1989, Can. J. Microbio 35: 1141-1 145; Doig et al ,1990, Infect. Immun. 58: 124-130). Anti- 1244 pilus monoclonal 6.45 maps to region 4 of 1244 pilin [Castπc and Deal, 1994, supra] and blocks adhesion to bovine tracheal cells (Saiman et al. ,1990, J. Infect. Dis. 161:541-548) indicating that region 4 contains the host binding site and so is a prime vaccine target.
Peptides corresponding to regions 1 and 4 have been synthesized and conjugated to ovalbum . Sera from mice immunized with these conjugated peptides recognize their respective regions of the peptide pm set referred to above and, most importantly, react with native pili as measured by Western blot and ELISA. These results show the feasabi ty of targetting pilus epitope through the use of conjugated peptides.
DISCUSSION
While glycosylation of prokaryotic proteins appears to be primarily restricted to the archaebacteria (Lechner & Wieland. 1989, Annu. Rev. Biochem. 58: 173-194), reports have suggested the association of polysaccharide with pili (Armstrong et al, 1981, J. Bacteriol. 145: 1 167- 1 176; Robertson et al, 1977, J. Gen. Microbiol. 102: 169-177). Virji et al ( 1993, Mol. Microbiol 10: 1013-1028) presented strong evidence (carbohydrate detection of blotted pilin and chemical removal of sugars) that Neisseria meningitidis pilin is glycosylated. Results presented in this paper suggest that pilin from P. aeruginosa 1244 also is glycosylated. The composition of the pilin-associated material remains to be determined, however several candidates, including the acidic moieties of the lipopolysaccharide core, alginic acid subunits, as well as other acidic elements or phosphoryiated compounds, must be considered. Limitations of SDS-PAGE prevent reliable molecular weight determinations of glycosylated proteins, a test which must await the use of a more accurate technique such as mass spectrometry. Linkage of glycosylated proteins is usually via the reducing end of an oligosaccharide sugar through an O- or N-linkage to the hydroxyl group of serine (or threonine) or the amide group of asparagine (Montreuil et al, 1986, In Carbohydrate Analysis, a Practical Approach, pp. 143-204. Edited by M. F. Chaplin & J. F. Kennedy. Oxford: LRL Press). The residues in the region of N-linked moieties have the characteristic consenus sequence N-X-S (or T). While this sequence may be found in the N. meningitidis pilin primary structure (Virji et al, 1993), it is absent in P. aeruginosa strain 1244 pilin, suggesting the presence of an N- linkage, a different sequence specificity, or the utilization of an alternative method of attachment. Clearly much work remains in the characterization of this pilin-associated material .
Previous work (Frost & Paranchych, 1977; Paranchych et al, 1979) has indicated that pili from P. aeruginosa strains PAO and PAK contained no sugar residues. Since the primary structure of pili from strain 1244 is distinctive when compared to those of strains PAO and PAK (Castric & Deal, 1994), pilus modification may represent a strain difference. P. aeruginosa strains producing pili antigenically related to those of strain 1244 are common among clinical isolates (Castric & Deal, 1994). Thus, pilin glycosylation by this bacterium
could be useful in clinical identification. Likewise, demonstration of the presence of the pilO gene could be of diagnostic value.
Since the absence of glycosylation seems to have no effect on either the formation of pilus fibres or extension and retraction of these fibres (as measured by bacteriophage sensitivity and twitching motility), the function of this modification is unclear. Because all pilin monomers appear to be modified [this must include both the pilin membrane pool (Watts etal, 1982c, J. Bacteriol. 152: 687-691) as well as pilus fibres], these glycoproteins must contribute greatly to the overall cell surface negativity. Bacterial avoidance of phagocytosis through inhibition of attachment has been well documented (Densen & Mandell, 1980, Rev. Infect. Dis. 2: 817-838). Diminished phagocytosis by neutrophils because of electrostatic repulsion has been demonstrated both by streptococcal M protein (Fischetti, 1989, Clin. Microbiol. Rev. 2: 285-314) and the pili of Neisseria gonorrhoeae (Heckels et al, 1976, J. Gen. Microbiol. 76: 359-364). Such a mechanism could also benefit P. aeruginosa when growing saprophytically where the avoidance of phagocytic amoebae could be an important survival mechanism.
Specific recognition by the pili allows attachment of the pathogen to host cells containing the proper receptors (Baker, 1993, In Pseudomonas aeruginosa. the Opportunist: Pathogenesis and Disease, pp. 7-24. Edited by R. B. Fick. Boca Raton: CRC Press; Heckels etal, 1976). The acidic modification might stabilize this attachment through the formation of salt bridges once specific binding had occurred. Alternately pilin glycosylation may be involved in specific or nonspecific adhesion to the host cell which is independent of pilin protein-mediated attachment. Adhesion studies utilizing PilO* and PilO" variants of P. aeruginosa strain 1244, as well as glycosylated and nonglycosylated pili, will be required to clarify these points.
The genetic evidence presented relates the presence of pilin glycosylation to a functioning pilO gene indicates that this process has a specific cellular role. This is strongly supported by the findings that the pilO gene is part of the pilA transcriptional unit. Although the pilA and pilO genes, along with a tRNAthr gene, are present in the form of an operon, two major transcription products are generated (an individual pilA message and a pilA/pilO/tRNA"" transcript) which are present in a ratio of about one hundred to one. Such results would not be unexpected as pilin is a major cell protein, while PilO would likely be required
in only catalytic or regulatory amounts. The difference in transcription levels could be the result of premature termination of message synthesis or relative instability of the transcript corresponding to the pilO region. The role of translation efficiency should also be considered a factor in differential gene expression since the beginning of the pilO message contains a short loop region which includes the start codon. Such a structure has been suggested to be able to significantly reduce translation (Gold, 1988, Annu. Rev. Biochem. 57: 199- 233), and may function to further control expression of a gene coding for a product required in small amounts when it shares a promoter with a gene coding for a product needed in large amounts.
The pilO gene product is predicted to code for a protein with a molecular weight of 50.862 using as start codon the ATG beginning at position 729 (Fig. 1 ). Hydropathy profile (Kyte & Doolittle, 1982, J. Mol Biol 157: 105-132) of the primary structure indicates that PilO contains nine hydrophobic regions which are flanked by clusters of charged residues. Secondary structure prediction (Chou & Fassman, 1974, Biochemistry 13: 21 1-221) suggests that large portions of these hydrophobic regions are composed of β-structure which are of adequate length to span the 3.0 nm membrane lipid core. Positively charged residues flanking the hydrophobic segments could be expected to stabilize this structure through ionic interaction with membrane phospholipids, while charged and polar residues in these regions would promote a surface solvent interaction on both sides of a membrane. Although the location of PilO has not been demonstrated, the high degree of hydrophobicity within the predicted transmembrane regions suggests that it resides in the cytoplasmic membrane. This location would be ideal if PilO functions catalytically on the periplasm side of the cytoplasmic membrane to transfer carrier lipid-bound oligosaccharide subunits to emerging pilin monomers.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Peter Castric
Alan Cross Jerald Sadoff
(ii) TITLE OF INVENTION: A Conjugate Vaccine Against
Gram-negative Bacterial Infections
(iii) NUMBER OF SEQUENCES: 5 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: John Moran
(B) STREET: USA MRMC - MRMC-JA
(C) CITY: FORT DETRICK, FREDERICK
(D) STATE: MARYLAND (E) COUNTRY: USA
(F) ZIP: 21702-5012
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette, 3.5 inch, 720 kB storage
(B) COMPUTER: IBM PC/XT/AT compatibles (C) OPERATING SYSTEM: MS-DOS
(D) SOFTWARE: WordPerfect 5.1 or ASCII editors (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: (C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: Provisional Application
60/009190 <B) FILING DATE: December 22, 1995 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Moran, John
(B) REGISTRATION NUMBER: 26,313
(C) REFERENCE/DOCKET NUMBER:
(ix) TELECOMMUNICATION INFORMATION (A) TELEPHONE: (301) 619-2065
(B) TELEFAX: (301) 619-7714
(2) INFORMATION FOR SEQ ID NO:1 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1386 base pairs
(B) TYPE: Nucleic acid (C) STRANDEDNESS:Double
(D) TOPOLOGY: Linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO:1 :
ATGCGAATTT GOCTAGCCTG GGAAAGGATG GGTAGGGCGT 40
CGCGTACTAT TCTATTATTG CTGATAAGTA TTCTTCTGCT 80 TTCTCCCGTT GTTTACTGCG GGGTTTCCAA GAACTGGCAT 120
GATCAGCAGC GAATACTCCA ATTGGTGGTG TTGAGTGGAT 160
CGTCACTCCT GCTGCTCTTT TCTTCTCGTC TGTCATTTGC 200
CAGAAGGATG GTTCAGGTAA CACTTTTGGT TATCTTGGGT 240
CTAGGCAGCG TTTCCGCATT TCTCTCCGCC AATCCTTCCT 280 GGGCATTCAA GGAATGGTCG GTATTCGCCG GCCTGATGCT 320
GTTTTCCTTC AATATATCCG CCAGCCCAGA GTGGGTTCGC 360
CGTATCGCCC TCTGGGGGGT GGTCGTGTTG GGAGGGTTCT 400
TCTGCTACCA GTTCCTGCTT TCCTATCTCG CGGCCTTCGT 440
CAGCGGACTC CGTGAGTTGA ATCCCAGGGT TTTGCTCAGC 480 GGCTTTTCCA ACGTCCGGAC CATGGGGCAG TTCCAGGCCA 520
TGCTGCTGCC GCTGATGGCT GCGCTGGGGT TGTACCTACG 560
AGAGACCGGG CGGTTCAGAC TGTCCTGGCT TGTCATGCTG 600
CTGCTGGCCA TCCAATGGTG CATCTCCTTC GCCTTGGCTG 640
GACGCGGGCT CTGGTTGGGT TTCGCCGTCG CGCATCTCGC 680 GCTTTGCTGG ATCGGCCCCG TGGGGCGCCG CTTTTTGATC 720
GTCCAGTTGT CCGCGGCATT CGTCGGGTTG GCGCTCTATT 760
TCCTGTTAAT GGTTGCCTTG CCGACCTGGC TCGGTATCGA 800
CATGACCCTC ATGTCCGGTA TGCGCAGTGG TCTGTCTCTG 840
CGCGACGTGT TGTGGCGAGA TGCCTGGGGC ATGTTCGTAG 880 CCCATCCTTT GCTTGGGGTC GGGCCCATGC ATTTCTCGGC 920
GGTGCCGAAC AGCGTCGGTG CCCACCCGCA CCAGATGCTG 960
CTGCAGTGGT TCGCTGAATG GGGCGGGGCC GCTGGCCTTC 1000
TGGTGGTTGG ACTGATGACC CTTGGTCTGC TTCGCGGCGC 1040
GCGTTACCTG CGTGAACAGG GCGATCCGAT GGACGCCGGA 1080 CTGTGGCTGG CCCTCGTTTC GGTCCTGGTC TTGGCCCAGG 1120
TGGACGGCGT GTTCGTCATG CCCTTCACCC AGACCGTATT 1160
GGCCTTGCTG GTAGGCATCG CCATGGCGCG CTGGTCGAAG 1200
CCGGTCGTGC CGTCCCCCGC ACAGCGCTGG CTCTGTCGGG 1240
GCCTGGCTGT CGTTGTCATT GTCGTGCTGG GGCGCGTGCT 1280
GCTGCTCGAG GTGCCGGGGC TGACCGCGGC CGAGGAGCGC 1320
TACCTGGAAA TCCACGGCGG CGGTGAGGCG CCACGTTTCT 1360
GGATTCAGGG TTGGATTCCC ATGTGA 1386
(3) INFORMATION FOR SEQ ID NO:2 : (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:461 amino acids
(B) TYPE: amino acids
(C) STRANDEDNESS: single
(ii) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Arg lie Trp Leu Ala Trp Glu Arg Met Gly Arg Ala Ser Arg
5 10 15
Thr lie Leu Leu Leu Leu lie Ser lie Leu Leu Leu Ser Pro Val
20 25 30
Val Tyr Cys Gly Val Ser Lys Asn Trp His Asp Gin Gin Arg lie 35 40 45
Leu Gin Leu Val Val Leu Ser Gly Ser Ser Leu Leu Leu Leu Phe
50 55 60
Ser Ser Arg Lys Ser Phe Ala Arg Arg Met Val Gin Val Thr Leu
65 70 75 Leu Val He Leu Gly Leu Gly Ser Val Ser Ala Phe Leu Ser Ala
80 85 90
Asn Pro Ser Trp Ala Phe Lys Glu Trp Ser Val Phe Ala Gly Leu
95 100 105
Met Leu Phe Ser Phe Asn He Ser Ala Ser Pro Glu Trp Val Arg
110 115 120
Arg He Ala Leu Trp Gly Val Val Val Leu Gly Gly Phe Phe Cys
125 130 135 Tyr Gin Phe Leu Leu Ser Tyr Leu Ala Ala Phe Val Ser Gly Leu
140 145 150
Arg Glu Leu Asn Pro Arg Val Leu Leu Ser Gly Phe Ser Asn Val
155 160 165
Arg Thr Met Gly Gin Phe Gin Ala Met Leu Leu Pro Leu Met Ala 170 175 180
Ala Leu Gly Leu Tyr Leu Arg Glu Thr Gly Arg Phe Arg Leu Ser
185 190 195
Trp Leu Val Met Leu Leu Leu Ala He Gin Trp Cys He Ser Phe
200 205 210 Ala Leu Ala Gly Arg Gly Leu Trp Leu Gly Phe Ala Val Ala His
215 220 225
Leu Ala Leu Cys Trp He Gly Pro Val Gly Arg Arg Phe Leu He
230 235 240
Val Gin Leu Ser Ala Ala Phe Val Gly Leu Ala Leu Tyr Phe Leu 245 250 255
Leu Met Val Ala Leu Pro Thr Trp Leu Gly He Asp Met Thr Leu
260 265 270
Met Ser Gly Met Arg Ser Gly Leu Ser Leu Arg Asp Val Leu Trp
275 280 285
Arg Asp Ala Trp Gly Met Phe Val Ala His Pro Leu Leu Gly Val
290 295 300
Gly Pro Met His Phe Ser Ala Val Pro Asn Ser Val Gly Ala His
305 310 315 Pro His Gin Met Leu Leu Gin Trp Phe Ala Glu Trp Gly Gly Ala
320 325 330
Ala Gly Leu Leu Val Val Gly Leu Met Thr Leu Gly Leu Leu Arg
335 340 345
Gly Ala Arg Tyr Leu Arg Glu Gin Gly Asp Pro Met Asp Ala Gly 350 355 360
Leu Trp Leu Ala Leu Val Ser Val Leu Val Leu Ala Gin Val Asp
365 370 375
Gly Val Phe Val Met Pro Phe Thr Gin Thr Val Leu Ala Leu Leu
380 385 390 Val Gly He Ala Met Ala Arg Trp Ser Lys Pro Val Val Pro Ser
395 400 405
Pro Ala Gin Arg Trp Leu Cys Arg Gly Leu Ala Val Val Val He
410 415 420
Val Val Leu Gly Arg Val Leu Leu Leu Glu Val Pro Gly Leu Thr 425 430 435
Ala Ala Glu Glu Arg Tyr Leu Glu He His Gly Gly Gly Glu Ala
440 445 450
Pro Arg Phe Trp He Gin Gly Trp He Pro Met
455 460 461
(4) INFORMATION FOR SEQ ID NO:3 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acids (C) STRANDEDNESS: single
Thr Val Glu Leu Val Ala Thr Leu 5 8
(5) INFORMATION FOR SEQ ID NO:4 :
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids
(B) TYPE: amino acids
(C) STRANDEDNESS: single
Thr Pro Thr Ala Trp Lys Pro Asn Tyr Ala Pro Ala Asn Cys Pro 5 10 15 Lys Ser 17
(6) INFORMATION FOR SEQ ID NO: 5 :
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids
(B) TYPE: amino acids (C) STRANDEDNESS: single
Arg Ala Val Ser Glu Val Ser Ala Leu Lys
5 10 Thr Ala Ala Glu Ser Ala He Leu Glu Gly
15 20
Lys Glu He Val 24
Claims
1. An isolated and purified pilO DNA fragment which encodes pilO or a portion thereof.
2. An isolated and purified DNA fragment according to claim 1, wherein said fragment has the sequence of SEQ ID NO: 1 or a portion thereof, or an allelic portion thereof.
3. An isolated and purified pilO DNA fragment according to claim 2 which encodes 461 amino acids or a portion thereof.
4. The DNA fragment according to claim 3, wherein said DNA fragment encodes the amino acid sequence according to SEQ ED NO: 2 or a portion thereof.
5. A DNA fragment according to claim 3, comprising at least 30 nucleotides of the sequence set forth therein.
6. A recombinant DNA construct comprising:
(i) a vector, and (ii) an isolated and purified pilO DNA fragment.
7. A recombinant DNA construct comprising according to claim 6, wherein said DNA fragment encodes 461 amino acids of pilO.
8. A recombinant DNA construct according to claim 6, further comprising a P. aeruginosa pilA gene.
9. A recombinant DNA construct according to claim 8, wherein the pil A gene is from P. aeruginosa strain 1244.
10. A recombinant DNA construct according to claim 9 wherein said construct is pPAC46.
11. A recombinant DNA construct according to claim 6. wherein said vector is an expression vector.
12. The recombinant DNA construct according to claim 7, wherein said DNA fragment encodes the amino acids sequence specified in SEQ ED NO: 2.
13. The recombinant DNA construct according to claim 6, wherein said vector is a prokaryotic vector.
14. A host cell transformed with a recombinant DNA construct comprising:
(i) a vector, and (ii) a DNA fragment which encodes 461 amino acids of pilO , or a portion thereof.
15. A host cell according to claim 14, wherein said cell is prokaryotic.
16. A host cell according to claim 15, wherein said cell is a Gram-negative bacterium.
17. A host cell according to claim 16, wherein said cell is a strain of P. aeruginosa.
18. A method for producing pilO which comprises culturing the cells according to claim 15, under conditions such that said DNA fragment is expressed and said pilO is thereby produced, and isolating saidp/7£>.
19. An isolated and purified pilA peptide conferring glycosylation to a pilin protein.
20. An isolated and purified pilA peptide according to claim 19, wherein said peptide has the amino acid sequence specified in SEQ ED NO:3, or a portion thereof.
21. An isolated and purified pilA peptide according to claim 19, wherein said peptide has the amino acid sequence specified in SEQ ED NO:4, or a portion thereof.
22. An antibody to a peptide having the amino acid sequence specified in SEQ ED NO:2, or any portion thereof.
23. An antibody to a peptide conferring glycosylation of pilin. having the amino acid sequence specified in SEQ ED NO:3 or a portion thereof.
24. An antibody to a peptide conferring glycosylation of pilin according to claim 23 wherein said peptide has the amino acid sequence specified in SEQ D NO:3 or a portion thereof.
25. An antibody to a peptide conferring glycosylation of pilin according to claim 23 wherein said peptide has the amino acid sequence specified in SEQ ED NO:4 or a portion thereof.
26. A method for the diagnosis of Gram-negative bacterial infections comprising the steps of:
(i) contacting a sample from an individual suspected of having a Gram-negative bacterial infection with an antibody to a pilin-glycan conjugate of a Gram-negative bacteria; and
(ii) detecting the presence or absence of Gram-negative infection by detecting the presence or absence of a complex formed between the pilin- glycan conjugate and antibodies specific therefor.
27. A method for the diagnosis of Gram-negative bacterial infection comprising the steps of :
(i) contacting a sample from an individual suspected of having a Gram-negative bacterial infection with a pilin-glycan conjugate of said Gram- negative bacteria; and (ii) detecting the presence or absence of a Gram-negative bacterial infection by detecting the presence or absence of a complex formed between the pilin-glycan and antibodies specific therefor in the sample.
28. A method for the diagnosis of P. aeruginosa from a sample using the polymerase chain reaction, said method comprising: (I) extracting DNA from the sample; (ii) contacting said DNA with
(a) at least four nucleotide triphosphates,
(b) a primer that hybridizes to pilO DNA, and (c) an enzyme with polynucleotide synthetic activity. under conditions suitable for the hybridization and extension of said first primer by said enzyme, whereby a first DNA product is synthesized with said DNA as a template therefor, such that a duplex molecule is formed:
(iii) denaturing said duplex to release said first DNA product from said DNA;
(iv) contacting said first DNA product with a reaction mixture comprising:
(a) at least four nucleotide triphosphates,
(b) a second primer that hybridizes to said first DNA. and (c) an enzyme with polynucleotide synthetic activity. under conditions suitable for the hybridization and extension of said second primer by said enzyme, whereby a second DNA product is synthesized with said first DNA as a template therefor, such that a duplex molecule is formed; (v) denaturing said second DNA product from said first DNA product;
(vi) repeating steps iii-vi for a sufficient number of times to achieve linear production of said first and second DNA products;
(vii) fractionating said first and second DNA products generated from said pilO DNA; and (viii) detecting said fractionated products for the presence or absence of pilO in a sample.
29. A Gram-negative bacterial infection diagnostic kit comprising an antibody according to claim 22 and ancillary reagents suitable for use in detecting the presence or absence of Sequestrin in a mammalian sample.
30. A P. aeruginosa infection diagnostic kit comprising primers specific for pilO and ancillary reagents suitable for use in detecting the presence or absence of pilO in a mammalian sample.
31. A therapeutic method for the treatment or amelioration of a Gram-negative bacterial infection comprising administering to an individual having such an infection an effective amount of an agent which inhibits pili function or expression in a pharmaceutically acceptable dose in a pharmaceutically acceptable excipient.
32. A multivalent vaccine against Gram-negative bacterial infections comprising a group of pilin-glycan conjugates of different strains or species of Gram-negative bacteria or any portion or allelic form thereof capable of eliciting protective antibodies against Gram-negative bacterial infections in a pharmaceutically acceptable excipient in a pharmaceutically acceptable amount.
33. A method for producing glycosylated pilin wherein the O- antigen from a specific strain of Gram-negative bacteria is added to pilin, said method comprising the steps of:
(i) introducing a vector containing pilA and pilO into said Gram- negative bacteria such that pilO is expressed and is capable of adding the O- antigen of said Gram-negative bacteria to said pilin; and (ii) isolating said glycosylated pilin.
34. A method for testing agents capable of inhibiting adhesion of Gram-negative bacteria pili to cells said method comprising:
(i) coating a surface with Gram-negative bacterial pili or a portion thereof; (ii) introducing test agent to said surface along with cells; and
(iii) measuring the ability of the agent to inhibit the adhesion of pili to cells.
35. A method for preventing Gram-negative bacterial infection or symptoms thereof said method comprising administering to a mammal a pharmaceutically effective amount of anti pilin-glycan conjugate antibodies or agents such that the function of Gram-negative pili is blocked, and the infection symptoms are ameliorated or prevented.
36. A method for large scale production of Gram-negative pili, said method comprising the steps of:
(i) transforming an RpoN" Gram-negative bacteria with a vector containing the pilin structural gene with or without pilO;
(ii) growing the transformed bacteria in broth culture with vigorous agitation; and
(iii) purifying pili from the supernatant fluid of said broth cultures.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU14619/97A AU1461997A (en) | 1995-12-22 | 1996-12-19 | A conjugate vaccine against gram-negative bacterial infections |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US919095P | 1995-12-22 | 1995-12-22 | |
US60/009,190 | 1995-12-22 | ||
US76817696A | 1996-12-18 | 1996-12-18 | |
US08/768,176 | 1996-12-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997023600A1 WO1997023600A1 (en) | 1997-07-03 |
WO1997023600A9 true WO1997023600A9 (en) | 1997-08-28 |
Family
ID=26679173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/019747 WO1997023600A1 (en) | 1995-12-22 | 1996-12-19 | A conjugate vaccine against gram-negative bacterial infections |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1461997A (en) |
WO (1) | WO1997023600A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7132101B2 (en) * | 2002-02-27 | 2006-11-07 | Duquesne University Of The Holy Ghost | Compositions and methods for eliciting an immune response to gram-negative bacterial infections |
EP2742355B1 (en) * | 2011-08-12 | 2018-12-19 | The Governors of the University of Alberta | Method of diagnosing bacterial infections using bacterial glycoproteins |
US9052314B2 (en) * | 2013-03-14 | 2015-06-09 | Silver Lake Research Corporation | Biomarkers for detecting the presence of bacteria |
-
1996
- 1996-12-19 AU AU14619/97A patent/AU1461997A/en not_active Abandoned
- 1996-12-19 WO PCT/US1996/019747 patent/WO1997023600A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6913907B2 (en) | Enterococcus faecalis polynucleotides encoding EF059 | |
EP0942983B1 (en) | Streptococcus pneumoniae antigens and vaccines | |
KR100619350B1 (en) | Modified immunogenic pneumolysin compositions as vaccines | |
EP0851927B1 (en) | Compounds for immunotherapy and diagnosis of tuberculosis | |
Von Specht et al. | Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins | |
AU718047B2 (en) | Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease | |
US6300102B1 (en) | Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins | |
NO332229B1 (en) | Proteins comprising conserved regions of Neissinia menigitidis surface antigen NhhA, pharmaceutical composition containing them, antibody, isolated nucleic acid, expression vector, host cell, methods and uses related to the proteins | |
JPH09503210A (en) | Vaccine against Blanchamella catarrhalis | |
CA2337638A1 (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
US7270827B2 (en) | Multivalent streptococcal vaccine compositions and methods for use | |
JPH10504444A (en) | Vaccine against Moraxella catarrhalis | |
US8114971B2 (en) | Nucleic acid molecules encoding proteins which impart the adhesion of Neisseria cells to human cells | |
Spinola et al. | The conserved 18,000-molecular-weight outer membrane protein of Haemophilus ducreyi has homology to PAL | |
EP0567470B1 (en) | Pseudomonas peptide composition and method for producing the same | |
US6872398B2 (en) | Conjugate vaccine against gram-negative bacterial infections | |
CA2719041C (en) | A method for identifying polypeptides which comprise a cross-reactive antigenic determinant | |
AU631378B2 (en) | Vaccines and diagnostic assays for haemophilus influenzae | |
WO1997023600A9 (en) | A conjugate vaccine against gram-negative bacterial infections | |
WO1997023600A1 (en) | A conjugate vaccine against gram-negative bacterial infections | |
US6335182B1 (en) | Recombinant Haemophilus influenzae adhesin proteins | |
US20030133943A1 (en) | Protective recombinant Haemophilus influenzae high molecular weight proteins | |
US7785609B1 (en) | Recombinant Haemophilus influenzae adhesin proteins | |
CA2294468A1 (en) | Compounds encoding the protective m-like protein of streptococcus equi and assays therefor | |
AU3796099A (en) | Assays using nucleic acid and amino acid sequences relating to helicobacter pylori |